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Duchenne Muscular Dystrophy (DMD) is a rare, X-linked degenerative neuromuscular disorder 
causing severe progressive muscle loss and premature death. While research in DMD is critical 
to advance treatment and care it also presents many challenges and sacrifices for families who 
are asked to participate. These barriers and impacts families incur can affect recruitment of 
research participants.  Poor recruitment constrains the ability to achieve and measure progress in 
clinical research, and consequently affects how well new therapies perform in the clinical setting.  
The purpose of the present study was to identify family barriers to research recruitment and 
participation in DMD research and to explore how these barriers impact families.   
In collaboration with the Cooperative International Neuromuscular Research Group 
(CINRG) academic clinical research network and associated Muscular Dystrophy Association 
(MDA) clinics, this qualitative study included parent-centered focus groups that were conducted 
at five sites:  Pittsburgh, PA; Washington, DC; Minneapolis, MN; Houston, TX; and 
Sacramento, CA.  A total of eight guided focus groups attended by 28 parents of boys or young 
men with DMD were audio-recorded and transcribed. Qualitative thematic analysis of focus 
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group transcripts was conducted to identify themes.  Major themes identified as perceived 
barriers to research participation included: 1) commitments; 2) fighting a new battle; and 3) the 
gamble.  Parents described the familial impacts of these barriers, which included financial 
burdens, family sacrifices, and psychological stress.   
Participating in research was shown to affect many aspects of participants’ lives and 
additionally had an impact on the entire family. These findings highlight the need for greater 
support and appropriate resources to alleviate potential barriers faced by families.  Genetic 
counselors are well suited to communicate research opportunities, address the specific needs of 
families, and assist with development of strategies to engage the DMD community in research.  
Identifying barriers of research participation and understanding how these barriers may impact 
families have significant public health implications which can provide information to improve 
research protocols, facilitate development of family resources, and influence public health 
policies to provide additional support to families and encourage greater research involvement. 
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1.0  INTRODUCTION 
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder resulting from mutations in 
the dystrophin (DMD) gene that encodes the dystrophin protein.  The X-linked condition is the 
most common form of childhood muscular dystrophy, affecting 1 in 3,500 to 1 in 6,000 male 
births.1; 2 DMD leads to progressive muscle deterioration and weakness in which individuals 
become non-ambulatory and develop cardiac and respiratory complications, eventually resulting 
in death occurring in the third decade of life.3; 4 
Although there is no cure for this degenerative condition, research for rare diseases is 
critical in order to enhance knowledge of the disease natural history, establish appropriate data 
for future treatment advancements, expedite new interventions, and ultimately provide the best 
treatment options.  Promising research in DMD has provided advances in treatment and care to 
improve the quality of life and life expectancy for individuals with DMD.5 
While current research in DMD has offered hope, it may present many challenges and 
sacrifices for families when asked to participate in research.6; 7 For rare diseases, recruitment and 
retention of eligible participants is a challenge, as sample sizes tend to be small and not all 
participants may fulfill enrollment criteria. 8; 9 Educational materials to connect participants with 
appropriate resources and research opportunities are not readily available to families. Travel and 
time commitments add additional challenges due to geographically dispersed participants, 
financial burden of transportation, and various lifestyle sacrifices.8; 9 Perceptions of risks and 
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benefits to research participation, vary between families and may raise uncertainty and fears 
resulting in some families declining to participate in research. 8; 10 These barriers not only add to 
the financial stress of families, but can also have negative emotional impacts and undermining 
effects on the family, which may prohibit study enrollment and contribute to loss of research 
participants.6 8; 9  
Qualitative research has been used to explore and understand perceptions of research and 
barriers to research participation.11; 12 Qualitative research methods can be useful to health care 
professionals, as they allow insight into human experiences, which can identify factors and social 
barriers explaining attitudes and behaviors that are difficult to deduce through quantitative 
methods.11 Thematic analysis is a widely used method in qualitative research that seeks to 
identify and describe patterns or themes within data.  Thematic analysis allows for a rich and 
detailed description of data.12 
The present study utilized qualitative thematic analyses to identify family perceptions and 
barriers to research participation and identified how these factors may impact families.  
Exploring barriers to research participation and how these barriers impact families may provide 
information to improve research protocols, increase research participation, and facilitate 
development of resources to alleviate these barriers. 
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2.0  RESEARCH QUESTIONS AND SPECIFIC AIMS 
2.1 RESEARCH QUESTIONS 
Question 1:  What are the perceived barriers to research participation amongst parents of boys 
with DMD? 
Question 2:  What impacts do these barriers have on families within the DMD community? 
2.2 SPECIFIC AIMS 
Aim 1: Identify potential barriers to research participation within the DMD community. 
Aim 2: Identify possible impacts of these potential barriers on families within the DMD 
community. 
 4 
3.0  BACKGROUND AND SIGNIFICANCE 
3.1 DUCHENNE MUSCULAR DYSTROPHY 
DMD is a degenerative, neuromuscular disorder primarily affecting males.  The disorder was 
first described in the 1860s and named after the French neurologist, Guillaume-Benjamin-Amand 
Duchenne.13; 14 DMD is the most common form of childhood muscular dystrophy, with an 
estimated incidence of 1 in 3,500 to 1 in 6,000 live male births.1; 2 In 2007, the CDC and 
investigators from the Muscular Dystrophy Surveillance Tracking and Research Network (MD 
STARnet) conducted a population-based study at four U.S. sites and estimated the prevalence of 
Duchenne/Becker muscular dystrophy to be 1.3 to 1.8 per 10,000 males aged 5 to 24 years.15 
3.1.1 Molecular Genetics 
DMD is caused by pathogenic variants in the DMD gene, localized to chromosomal region 
Xp21.2.  Mutations are predominately deletions or duplications of one or more exons, but can 
include small deletions and point mutations. The DMD gene is the largest gene in the human 
genome spanning 2.4 Mb and encompassing 79 exons.16  The gene encodes for the protein 
product, dystrophin, which is an essential part of the dystrophin-glycoprotein complex that links 
the cytoskeleton to the extracellular matrix and provides stability and protection of muscle 
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structures. Absence of the dystrophin protein causes muscle membrane dysfunction leading to 
progressive muscle degeneration.17   
3.1.2 Inheritance 
DMD is inherited in an X-linked recessive manner.  About 60% to 70% of all cases are inherited 
from a carrier female, while one in three individuals with DMD is affected as result of a de novo 
mutation.18 Carrier females have a 50% risk in each pregnancy to pass on the gene mutation.  
Males who inherit the mutation are affected with DMD, while females who inherit the mutation 
are carriers of DMD.19 
3.1.3 Clinical Course 
If evaluated in the newborn period, individuals with DMD present with elevated serum levels of 
creatine kinase (CK).  However, CK evaluations are not routinely ordered during the newborn 
period and patients are rarely identified based on CK levels alone.  Diagnosis is typically delayed 
and most often established between the ages of 4 and 5 years.20; 21; 22 The recognition of early 
symptoms, such as general motor delay, occur on average at age 2.5 years and are originally 
detected by parents or caregivers.20 Symptoms progress and become more pronounced by the age 
of 5 years, as individuals may present with frequent falls and inability to keep up with peers.  
Other symptoms may include cognitive delays, articulation difficulties, speech delays, and 
behavioral issues.20; 21; 22 
DMD is characterized by skeletal muscle weakness and reduced mobility leading to loss 
of ambulation typically by the age of 13 years.  Muscle deterioration also results in orthopedic 
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complications such as scoliosis and osteoporosis.  The progressive course of the disorder 
ultimately results in premature death, most often attributable to cardiomyopathy and respiratory 
failure.3; 23 However, the administration of corticosteroid therapy has been shown to delay 
progression of muscle weakness, reduce risk of scoliosis, and preserve ambulation.24; 25 Milder 
allelic forms of the disorder exist such as, Becker muscular dystrophy (BMD). BMD is 
characterized by less severe and later onset of symptoms, but will not however, be the focus of 
this study. 
DMD follows a progressive course with five stages of disease classification.26 In stage 
one (presymptomatic), developmental delay is noted with absence of gait disturbance and 
typically no respiratory complications.  In stage two (early ambulatory), symptoms may include 
Gowers’ sign, waddling gait, toe walking, difficulties climbing stairs, and risk for respiratory 
problems.  Stage three (late ambulatory) includes difficulties rising from the floor, increasingly 
labored gait, and risk for cardiac and respiratory problems.  In stage four (early non-ambulatory), 
individuals have an increased risk to develop cardiac and respiratory complications, are able to 
maintain posture, may develop scoliosis, and generally able to self propel for some time.  Stage 
five (late non-ambulatory) includes reduced upper limb function, limited ability to maintain 
posture, and high risk for respiratory impairment and cardiac issues.  Established care guidelines 
provide care considerations specific to each stage of disease and provide a framework for 
multidisciplinary care and management.26 
Advancements in medical care have improved quality of life and with assisted 
ventilation, the average life expectancy is approximately 35 years.3; 27  Despite improvements in 
medical care, there is still no cure for this debilitating disorder.  Promising research has provided 
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hope for development of new therapies and is essential to enhance knowledge of the disease and 
ultimately provide the best treatment options. 
3.2 DMD AND RARE DISEASE RESEARCH 
Many rare diseases, such as DMD, rely solely on research to provide treatment options.  Rare 
diseases are often life-altering, require serious medical attention, and many result in early death.  
Therefore, research is crucial for developing appropriate standards of care, advancing 
understanding of the disease, and improving quality of life.5 The complexity and burden of a rare 
disease diagnosis, along with the relatively small number of affected individuals, host a number 
of challenges to recruitment and retention of research participants and ultimately complicates the 
development of effective treatment strategies.8 These issues have led to growing acceptance and 
public health recognition of rare diseases, including DMD.28 
3.2.1 Classification of Research 
Research encompasses a broad spectrum of clinical studies and can be classified into two main 
categories: interventional studies and non-interventional studies, also known as observational 
studies.  Both interventional and non-interventional studies play an important role in advancing 
treatments and improving quality of life for individuals with DMD.  The designation of research 
in the present study will focus on research as a whole and include both interventional and non-
interventional studies. 
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Interventional studies seek to evaluate the safety and efficacy of a specific intervention.  
Interventions may include drugs, devices, medical procedures, and/or behavioral interventions 
such as changes to lifestyle and diet.  Some studies may compare new interventions to placebos 
or current medical approaches in order to measure the impacts of a treatment or preventive 
measure on the disease.29 The Food and Drug Administration (FDA) categorize interventional 
studies for drug development into different research phases based on the characteristics of the 
study.  Studies can range from phase I trials, which assess initial safety of a drug within a small 
population to phase III trials, which include larger randomized controlled studies to further 
confirm safety and efficacy before FDA approval of the drug.29 
Non-interventional studies, also known as observational studies, seek to assess health 
outcomes of a specific disease or medical intervention in a naturalistic setting consistent with the 
current standards of care and typically within a large population.  Participants are not assigned to 
an intervention as part of the study protocol, but may be assessed in a similar fashion as what is 
applied in standard clinical practice.  Non-interventional studies may provide insight to influence 
treatment methods and may include, but is not limited to, surveys, questionnaires, interviews, 
and natural history studies.29 Natural history studies are conducted to increase disease knowledge 
and better characterize the disease course.  These studies are beneficial to evaluate outcome 
measures that can be used in interventional trials.30 
3.2.2 Importance of Rare Disease Research 
Research is required in order to provide treatment to individuals within the rare disease 
community.28 Research provides knowledge regarding the diagnosis, natural history, treatment, 
and prevention of a particular disease.  The devastating nature of DMD, unmet medical needs, 
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and urgency for new therapeutic strategies, highlight the significance of ongoing research. As 
there is currently no cure for DMD, novel treatment strategies including exon skipping, cell 
therapy, and gene replacement hold potential to improve quality of life in individuals with 
DMD.5 
3.2.2.1 Public Health Impact 
The FDA defines a rare disease as a disease or condition affecting less than 200,000 people in 
the United States.  Prior to the Orphan Drug Act of 1983, research and development of 
treatments for rare diseases had been neglected.  The law was passed by US Congress to 
facilitate the development of drugs and treatment for rare diseases.  The Department of Health 
and Human Services National Commission on Orphan Diseases in 1989, heard testimonies from 
patients, families, physicians, and researchers who raised awareness about the challenges of rare 
diseases and highlighted public health issues.  Stakeholders emphasized barriers to rare disease 
research including limited disease knowledge and lack of effective treatments to satisfy the 
unique needs of the rare disease population.28 
Lack of disease knowledge is one of the greatest barriers to the diagnosis, treatment, and 
prevention of rare diseases.  Research is designed to enhance medical knowledge of a disease in 
effort to assist with the diagnosis, identify disease risk factors, evaluate current interventions, 
prevent development and/or recurrence of a condition, explore methods for improving quality of 
life and supportive care, and ultimately establish effective treatments.  Without knowledge of a 
disease, designing and implementing treatment strategies become a challenge.28 Research, such 
as natural history studies, aim to gather data regarding disease progression and response to 
treatments and therapies across a lifespan.  Natural history studies, along with other non-
interventional studies, provide useful information to enhance overall knowledge of the disease 
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progression, identify genetic variability, assist with design of future studies, develop new clinical 
trials, and establish clinical endpoints.30; 31 
Rare diseases present many challenges to the medical community, but over the years, 
have gained public health recognition to support research efforts.28; 32 However, most rare 
diseases, including DMD, lack effective treatment options due to various disease-related 
challenges.  The development of treatments for rare diseases is a complex, lengthy, and an 
expensive process, which limit approved treatment options available to patients.33 As a result, 
many patients and physicians have resorted to the use of non-FDA approved drugs or drugs 
approved by the FDA for other conditions, not specific to their diagnosis.28 Most rare diseases, 
including DMD, are serious, life-threatening conditions typically affecting vulnerable 
populations.  The devastating nature of such rare diseases, highlight the urgency for effective 
treatment options and assessment of the safety and efficacy of new therapeutic strategies, as 
research is crucial to the understanding, development, and approval of effective treatments.28; 32 
3.2.2.2 Promising Treatment Strategies for DMD 
For a disease in which there is ultimately no treatment, research provides the greatest hope for 
families within the DMD community.  As the standard of care for treatment of DMD is 
essentially limited to the use of steroids to preserve ambulation, novel treatment approaches 
currently undergoing research, including exon skipping, cell therapy, and gene replacement have 
shown promise.5 
 A major advancement in DMD research has utilized the strategy of exon skipping.  As 
DMD occurs as a result of a frame-shift mutation in one or more exons of the dystrophin gene, 
exon skipping omits specific exons in effort to restore the reading frame.  The drug used in this 
approach has shown the greatest potential to become clinically approved for individuals with 
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specific exon deletions.34 Another approach to treatment that is currently underdoing research is 
cell therapy.  Due to the recurrent breakdown of muscle fibers associated with DMD, cell 
therapy aims to replace the loss of muscle fibers through delivery of normal myogenic cells or 
pluripotent stem cells.35 Gene replacement is another promising therapeutic approach and in 
theory, would provide long-term treatment benefits.  The goal of gene replacement is ideally to 
replace the defective dystrophin gene with synthetic counterparts to facilitate functioning of the 
gene.34; 36  
Although there remain many challenges to overcome with these research approaches and 
much research is still required before these treatment strategies become clinically available, it is 
hypothesized that these approaches will have a major impact on the future of DMD and the 
quality of life for individuals affected with this disease.5 
3.2.3 Recruitment and Retention Challenges 
Recruitment and retention of eligible participants is a challenge for most rare disease researchers.  
Ability to achieve and measure progress in clinical research is constrained by these recruitment 
challenges and low levels of participation. 8; 9  Given the small number of affected individuals, 
diagnostic complexities, inconvenient trial designs, and limited access to resources, timely and 
adequate recruitment is difficult to achieve.37 Maintaining recruitment numbers can help provide 
smooth transitions through various phases of clinical trials and assist with advancements in 
development and application of new therapeutic strategies into the clinical setting.  However, 
various challenges to study recruitment and retention hinder the progress for development of 
effective treatments and add to barriers already faced by researchers and families.8; 9 
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3.2.3.1 Limited Patient Population 
As with any rare disease, DMD affects a relatively small number of individuals and is further 
limited by its pattern of inheritance to males, which present challenges to satisfying study 
enrollment goals.  Given the small pool of eligible participants, researchers find themselves 
competing to recruit the same study population.37  ClinicalTrials.gov is a web-based resource 
that provides access to research studies for a variety of conditions.  All government-funded 
research is required to be posted on ClinicalTrials.gov.  Additionally, many industry groups or 
pharmaceutical companies may post their research studies, but are not required to do so.  
Therefore, not all studies will be listed in this resource, but it does serve as a central repository 
for most research studies.  As of March 2015, there are approximately 25 studies in the United 
States openly recruiting DMD patients and/or families, which would require over 3,200 
participants to fulfill recruitment needs.  Most research in DMD desires younger study 
participants at an early disease stage.  Strict criteria typically exclude most non-ambulatory 
individuals with DMD and those at a critical stage of the disease, where hopes of treatment and 
advancing quality of life are diminished.6 Of the 25 studies openly recruiting DMD patients 
and/or families, only 11 studies are recruiting non-ambulatory and/or older patients.  Therefore, 
recruitment of eligible participants is a struggle for many researchers in DMD studies as well as 
patients and families in the DMD community that wish to participate. 
3.2.3.2 Diagnostic Delays and Disease Complexity 
Despite availability of diagnostic testing, including molecular genetic testing, there is still a 
delay in recognition of early signs and symptoms of DMD.20 Lack of disease awareness by 
families and health care providers may result in a diagnostic odyssey leading to a delay in 
diagnosis or in some cases, no diagnosis at all.  Obtaining an accurate and timely diagnosis is 
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essential to provide appropriate care and discussion of research opportunities.38 Most research 
studies require diagnostic testing to confirm a DMD diagnosis in order to meet eligibility criteria.  
This holds especially true to interventions that are mutation-specific, such as exon-skipping 
studies.  Delays in the diagnosis may consequently delay research participation, as research may 
not be discussed with health care providers until patients are at an advance stage of the disease 
process and therefore, narrowing research opportunities for which a patient is eligible for. 33 
As there is currently no cure for DMD, the diagnosis alone can be quite burdensome and 
complex to manage. DMD is a disabling disease that severely impairs muscle function, 
significantly limits physical abilities, and shortens life expectancy, which make continuous 
involvement in research studies a difficult task for families. Travel to research centers may 
become an overwhelming barrier to participation, due to physical impairments associated with 
DMD. Therefore, diagnostic delays and disease complexity pose challenges for not only 
recruitment but retention of study participants as well.39    
3.2.3.3 Study Design 
A randomized controlled trial is a well-adopted study design used for most clinical trials.  The 
study design randomly assigns participants to either a placebo (or non-interventional therapy) or 
to an experimental drug (or interventional therapy).  However, for a disease in which there are 
limited effective treatment options, many potential participants are opposed the concept of 
randomization and reluctant to enroll in placebo-controlled studies.37 
Once participants have been recruited for a study, retention of study participants is an 
essential element to study success and completion.  Study visits for DMD are often time 
consuming and require frequent research visits in which participants may undergo multiple 
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testing procedures.  Therefore, if study protocols do not include strategies to relieve stress 
associated with study participation, then families are more likely to drop out of the study.8   
3.2.3.4 Limited Resources 
In a disease population, such as DMD, where effective treatments are scarce, development and 
coordination of resources are imperative to meet the unique needs of the DMD community.  
Collaboration between stakeholders is needed to enhance access to resources including research 
funding, educational materials, and partnership with support organizations and patient registries.  
However, satisfying the unique needs of the rare disease population has presented challenges due 
to competitive funding, lack of clinical resources, and fragmentation of resources and support 
organizations.28 
 Access to resources needs to be considered when designing and implementing a research 
study in order to ensure successful recruitment and completion of the study.  Although the 
Orphan Drug Act increased industry attention to rare diseases, research is still in competition 
with common diseases, which makes obtaining research funding even more challenging to the 
rare disease population.37 Additionally, lack of clinical resources and educational materials for 
both families and clinical staff become a hindrance to the recruitment process.  Geographic 
dispersion of study participants requires appropriate funding and multiple research centers in 
order to carry out study protocol and fulfill enrollment needs.8 
Research studies in the DMD population can be expensive and rigorous, requiring 
collaboration between multiple parties including investigators, physicians, and patient families.  
Many active support organizations and patient registries are available in the DMD community 
but a lack of coordination between these entities presents additional challenges to recruitment.40 
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Clinic providers, including genetic counselors, play a significant role in recruitment and retention 
of research participants by communicating research opportunities to patients and their families.8 
Organizations and institutions with minimal infrastructure may not be equipped to facilitate an 
appropriate level of communication between researchers and families and therefore, fail to 
identify eligible participants and connect families to research opportunities. 
3.3 FAMILIAL PERCEPTIONS OF RESEARCH PARTICIPATION 
Understanding family perceptions of research participation can help clarify the rationale behind 
families electing or declining to participate in research.  Interestingly, studies have found that 
what physicians identify as likely important factors to families were not reported as important 
factors by families themselves.41 This disconnect emphasizes the needed to better understand 
family perspectives in order to bridge this gap and assist with recruitment efforts. 
Studies have been conducted to identify family perspectives, motives, barriers, and 
impacts of research participation within various disease populations, most prevalently within the 
cancer population.42 Studies within the DMD community have explored barriers and family 
impacts associated with the disease diagnosis; however, studies have not focused specifically on 
research participation within the DMD community.  Although one can hypothesize familial 
perceptions and expectations of research may overlap across varying disease populations, parents 
of children diagnosed with a progressively fatal disease, such as DMD, may face different 
challenges compared to children with cancer or other disease diagnoses.43 These differing 
circumstances further highlight the significance of the present study to identify barriers and 
family impacts of research participation that is unique to the DMD community. 
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3.3.1 Motivations and Perceived Benefits 
3.3.1.1 Altruism 
Altruism has been cited in several cancer-related studies and in some DMD studies as a major 
motivation for research participation.6; 41; 44 It has been speculated that participants in genetic-
related research may be more willing to participate primarily because research may benefit future 
generations and/or family members.  Studies report participants are more likely to be altruistic 
when research involves little effort or limited risks and when the personal benefits are similar to 
that for others.44 Another reported possibility, which may be the case for the DMD community, 
is that participants are more willing to be altruistic when there are no therapeutic options 
available, even in cases that may be associated with high risks.41 Studies have shown that 
research participants felt it is their obligation to help future generations and those within the 
disease community.6; 44   
3.3.1.2 Personal Benefit 
Studies related to DMD and other diseases have identified personal benefit as a motivator of 
research participation.  Although the perception of personal benefit is variable and subjective to 
the individual, some studies have reported specific benefits including, health improvements, 
increased medical attention, improved knowledge of disease, and promotion of self-sufficient 
care.6; 41; 45 
 In a study, which described expectations and experiences of parents involved in a DMD 
clinical trial, all parents expected some form of direct benefit, which was reported as their 
primary motivation for enrolling in research studies.6 The majority of parents hoped for health 
improvements, such as improving quality of life, slowing disease progression, and improving 
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strength, endurance, and cognitive function.6 Another study, assessed perceptions of research 
participants for other diseases, including cancer, had similar findings.41 The study also found that 
participants felt they received more medical attention during the research process than during 
routine medical visits.  Participants felt research in the rare disease population was the only 
option to obtain access to new therapies and in some cases receive free healthcare and diagnostic 
testing that would otherwise, not have been covered by insurance.41 However, as financial 
compensation was a contributing factor for participants, it is generally not the primary 
motivation for research participation.  Participants additionally reported that the increased 
medical attention from the research team allowed them the opportunity to learn more about the 
disease and allowed participants to become more self-sufficient in their care.41 
3.3.1.3 Hope 
Following a diagnosis, some parents have been instructed by their physicians to just take their 
sons home and love them, which may destroy any vestige of hope for these families.  In many 
disease communities, including DMD, hope provides psychological benefits and serves as a 
means of coping with this life-limiting disease.43 To some families, research represents the 
possibility of a cure and having an opportunity to participate in an endeavor, which may prolong 
life and allow hope to be maintained in families.  Therefore, some families turn to research as a 
source of hope and may be more accepting of risks associated with research participation in a 
quest for a cure.6 
3.3.1.4 Trust and Positive Relationships 
Building trust and establishing positive relationships with the research team has been highly 
valued by participants and their families.6 Studies have shown that research participants are more 
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likely to remain in studies when connected with a caring, respectful, and responsive research 
team.  Additionally, individuals who had a positive research experience are also more likely to 
remain in the study and participate in future studies.41 A common contributing factor to a 
positive research experience was development of close relationships with the research team.  A 
study that looked at expectations and experiences of parents involved in research for DMD, 
found these relationships were significantly important when participants felt threatened and 
overpowered by consequences of the disease.6 One study found that many families felt they 
received more attention and care during the research process than during routine medical care.  
These families perceived research participation as an opportunity to develop a closer relationship 
with their physicians and gain additional access to medical care.41 
 Additionally, establishing positive relationships with the healthcare team resulted in 
greater trust in healthcare providers.  Studies conducted within the DMD community have shown 
that families rely on their physician to educate them about research opportunities for which their 
child may be eligible for and provide guidance to the family in the decision making process.6 
Healthcare providers, including genetic counselors, can play a significant role in the educational 
aspect of research studies and provide assistance with recruitment and retention of research 
participants by communicating research opportunities.8 
Healthcare providers can also connect patients and their families to research registries.  
The development of patient registries, such as DuchenneConnect, has gained increasing 
popularity within research communities. Patient information including genetic mutation(s) and 
medical history is stored in a database and used to notify patients of research opportunities, assist 
in developing new clinical trials, and serve as a resource to clinicians and researchers by 
providing aggregated, de-identified data.46 Patient contact registries provide increased access to 
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research opportunities and have the potential to serve as a powerful recruitment tool for research 
teams.47 
Additional outcomes of research involvement may include connecting families with one 
another, development of strong relationships among committed parents, and increased 
engagement within the DMD community.  Although the challenges of the disease has substantial 
impact on families, the desire for a cure has provided motivation for many families to unite and 
form advocacy groups to promote and fund research within the DMD community.32 
3.3.2 Therapeutic Misconception and Blind Optimism 
As previously discussed, many parents of a child diagnosed with DMD indicate hope as a motive 
for participating in research.  However, hope may have the potential to stimulate forms of 
misconception linked to research.43 Increased community and individual involvement with 
research studies and development of new therapeutic strategies may bring about heightened 
assumptions regarding access and participation in research.  These assumptions may encourage 
unrealistic expectations and ultimately lead to misconceptions associated with research 
involvement.6 
Increased expectations or assumptions of research involvement may result in participants 
misconstruing the primary purpose of research as directly benefitting, opposed to providing a 
contribution towards disease knowledge, regardless of potential benefits. This phenomenon has 
been defined in previous literature as therapeutic misconception. Some studies have suggested 
that research mechanisms and specific interventions may prompt therapeutic misconception.6; 48   
This is particularly relevant to the DMD community, as mutation-specific therapies, such as exon 
skipping, may have heightened expectations for both families and clinicians.6 
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Studies have identified inadequate education on research expectations in which 
participants lack understanding of what will happen in a study.  Consequently, parental 
expectations of research emerge from a variety of sources, including patient advocacy 
communities, which may inaccurately enhance expectations.6; 41  The progressive and fatal nature 
of DMD leaves many families sensitive to any hope for potential treatment options.  Therefore, 
families may become vulnerable to exaggerated hope and underlying optimism that may present 
on patient organization websites, social media, parent support groups, and other resource 
avenues.  The effect of overly optimist advocacy of clinical trial participation within the DMD 
and BMD community has been described as a ‘collective therapeutic misconception.’43 
Unrealistic or ‘blind optimism’ is another phenomenon, which has been described in 
early-phase oncology studies.49 This concept has been supported by a study, which characterized 
experiences of parents involved in a clinical trial for DMD and BMD.6 The study found 
participants displayed optimistic bias toward study benefits.  Participants in the study were asked 
to differentiate between the terms expectations and hope associated with research participation.  
Most parents defined research expectations as what they thought would happen in the study and 
associated the term with feelings of confidence.  However, hope was most often used as the 
default terminology when discussing expectations for a study.  Parents defined hope as the best 
possible outcome and associated the term with feelings of optimism.  Confusion between the 
terms expectation and hope may result in misconception for families and potentially suggests a 
dissonance between the understanding and emotional representation of a study.6 
As all research must eventually come to an end, some parents expressed understanding of 
research termination, while other parents have reported feeling powerless and having a loss of 
hope due to what they believe as a sudden and unexpected halt of a study.6 Up until the traumatic 
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termination of a research study, most parents felt a supportive connection with the research team.  
Following an unsuccessful study or termination of a study, parents felt cut off in the relationship 
and lack of communication as to future directions and the path moving forward.  These parents 
felt greater support should have been provided for the possibility of a study ending unexpectedly.  
Other parents felt better prepared as research teams provided parents with support and 
connection to advocacy groups.6 Therefore, inaccurate expectations of families encourage needs 
to explore participant experiences and potential barriers to research participation. 
3.3.3 Potential Barriers  
DMD is a complex and life-limiting disease, which presents significant challenges to families.  
Families face emotional and social distress, financial burdens, and are forced to make daily 
sacrifices affecting employment, education, and family relationships.50 These challenges 
overburden families making it difficult to participate in research.  The progressive and 
unpredictable nature of DMD can overwhelm parents adding to fears of the unknown associated 
with DMD.50 This state of apprehension, along with potentially invasive research procedures, 
deters many families from participating in research.6 Additionally, complex research protocols, 
lengthy informed consents, and negative experiences make recruiting and retaining research 
participants difficult.28; 41 
3.3.3.1 Disease-Related Challenges 
Living with a rare disease, such as DMD, requires learning to live with a condition in which 
there is limited treatment and understanding by family, clinicians, researchers, and the 
community.28 Despite many research efforts, DMD lacks effective treatments, requires numerous 
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medical appointments, and consequently sends many families into a diagnostic odyssey of 
countless tests.52 Psychological and social consequences due to diagnostic delays and limited 
access to genetic testing can result in serious health implications.50 DMD can be difficult to 
manage, as there are limited treatment options and care requires a multidisciplinary team of 
specialists.  Therefore, challenges associated with the diagnosis of DMD are complex and 
encompasses social, emotional, and financial costs.28; 51; 52 50 
A substantial amount of research has highlighted the significant emotional burden 
associated with a genetic condition.52; 53   Emotional and social costs to families can be extensive 
and include psychological stress, feelings of isolation, concerns of support, and social inequality. 
Many parents of boys with DMD live in constant fear for theirs sons.  Parents fear a shortened 
lifespan, pain, injury, and unknown consequences for their sons that may occur due to this 
progressively fatal disease.52; 53  With progressive and fatal disorders, such as DMD, time can be 
the ultimate enemy and present many pressures that affect the decisions of parents to involve 
their child in research studies.6 One study found that many parents associated doing nothing with 
accepting the fate of early death and felt it their responsibility to enroll their child in research 
before loss of ambulation.8   However, other parents felt time spent in research studies eliminated 
opportunities for families to partake in normal life activities.  Families find themselves at a 
constant battle with time and how best to utilize the time they have while their son is still living.8   
This struggle combined with many societal factors, limit families’ chances for normalcy.  
Many parents feel pressured to stay strong for the benefit of their sons and create self-imposed 
boundaries, which may prohibit parents to appropriately cope and/or discuss their son’s 
diagnosis.54 Patients and families are forced to become educated advocates and actively involved 
in their own care, including making household additions such as ramps, widening doorways, and 
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even relocating to a handicap equipped residency.54 Family dynamics may also change and 
include transitions such as siblings involuntarily adopting caretaker roles or receiving inadequate 
attention from parents.51; 53; 55 
Along with emotional and social consequences, the diagnosis of DMD is accompanied by 
a variety of costs and substantial economic burden that families must endure.  Research 
participants require the use of multiple healthcare resources, such as medications, various 
procedures, medical devices, hospital admissions, and a number of doctor visits.28 Theses 
financial challenges contribute to barriers in research participation as many families suffer a loss 
of wages and employment opportunities.  One study found parents experienced a decrease in 
household income and reduction or cessation of employment as a result of their son’s diagnosis 
of DMD.56 The study estimated the mean loss in work hours to be one day per workweek.  The 
study estimated the corresponding household burden to be between $58,440 and $71,900, and the 
mean per patient annual direct cost was estimated to be $28,590 for the United States, which is 
seven times higher than the mean per-capita health expenditure.  Additionally, the total societal 
burden was estimated to be between $80,120 and $120,910 annually per patient, which increased 
with disease progression and the national burden of DMD in the United States was reported to be 
$1,217,373,000.  Addressing financial adversity can assist with full understanding of therapeutic 
benefits and help construct a reasonable evidence-based health policy.56 
3.3.3.2 Uncertainty 
The challenges of many rare disease diagnoses present many life stressors, including living with 
uncertainty.  This level of uncertainty relates to a number of factors that can be associated with a 
shortened lifespan and unpredictability of the disease.  These factors contribute to the risks and 
fears perceived by families affected with DMD.  One of the most prevalent issues associated 
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with rare diseases is the fear of the unknown due to limited disease knowledge and information, 
which leaves many families feeling isolated and potentially unwilling to participate in research.28 
The sheer effort of moving forward for these families becomes a challenge due to an uncertain 
future from both a medial and psychosocial standpoint.52 
Parents of boys or young men with DMD possess a desire to act within the best interest 
of their child.  In the context of research participation, parents admitted fear of making the wrong 
decision regarding enrolling their son in a research study, but also acknowledged the importance 
of their son’s autonomy when deciding to participate in research.6 In a rapidly progressing 
incurable disease, such as DMD, many parents felt greater urgency to expose their children to 
promising research treatments before they became nonambulatory and the window of therapeutic 
opportunity diminished.9 However, other parents had reservations for research participation due 
to risks involved in exposing their sons to unknown or untested substances, fear of being a 
guinea pig, and risking the chance of having their son receive the placebo rather than the 
intervention.  For a disease in which lifespan is reduced, parents felt there are ethical concerns 
centered around placebo-controlled trials and that all families willing to participate should not be 
subjected to the placebo.9; 44 
3.3.3.3 Consent Process 
Before individuals participate in research they must go through the informed consent process.  
This process includes an explanation of research expectations, requirements, risks and 
discomforts, benefits, purpose of the research, and rights to withdrawal or discontinue 
participation.  Although the informed consent process is vital to research participation, studies 
have shown that participants did not fully understand the research protocol and did not recall 
receiving consent forms that appropriately addressed the full extent of research requirements.41; 
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57; 58 Additionally, individuals were unaware of the time commitments associated with the 
research protocol and participation, which may be attributed to participants not listening or 
attending to the consent process, or may be due to the extended length and complexity of 
informed consent forms.41 Families preferred interacting with knowledgeable personnel during 
the informed consent process and appreciated simplified forms displaying clear basic language.  
Families also admitted to disregarding risks because they had invested their utmost trust in the 
institution and their healthcare providers to protect their safety and keep their best interest in 
mind.41 It can be hypothesized that these perceptions of the informed consent process are highly 
applicable to the DMD community given the disease complexity and psychological sequelae.  
3.3.3.4 Negative Experiences 
Positive research experiences are more likely to promote continued research participation. 
Similarly, negative experiences with research result in individuals terminating research 
participation.6 Studies have shown that the main factors contributing to negative research 
experiences include pain and discomfort associated with invasive procedures, adverse side 
effects related to the research intervention, demanding studies and participant inconvenience, 
poor study organization and appointment delays, and unprofessional study teams.41;59 
Participants felt these factors played a significant role in determining whether they continued 
with current trials and/or whether they returned to participate in subsequent studies.41; 59 
 In addition, studies have found that research participants desired receipt of study 
outcomes and results of testing as part of research protocol.41 Providing this information made 
parents feel valued and that their participation contributed to the disease community.  
Participants expressed some disappointment when research information was not shared.  The 
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level of disappointment may play a role as to which research studies individuals elect to pursue 
and whether they decide to enroll in future studies.41 
3.4 QUALITATIVE RESEARCH 
Qualitative research is a form of research which encompasses methodologies from a variety of 
disciplines that can be used to study and understand phenomena and the perceptions that 
influence human behaviors.  Qualitative research methods can be useful to health care 
professionals, as they allow insight into human experiences, which can identify factors and social 
barriers and explain attitudes and behaviors that are difficult to deduce through quantitative 
methods of data analysis.11; 12  DMD is a complex disease resulting in burdensome medical and 
psychosocial sequelae. Therefore, relying solely on quantitative methods does not provide full 
understanding of the psychosocial elements and interpretation of the particular subject matter 
associated with DMD.  Information concluded from qualitative research has been utilized in 
cancer and some rare disease populations to assist with recruitment efforts and study design of 
future research.8; 42  Qualitative research plays a pivotal role in ensuring that advancements in 
research and therapeutic methods are developed and executed in the best interest of families.11  
There are many approaches to qualitative research and a number of methods, which can 
be implemented to characterize the data.  Thematic analysis is an analytic method in qualitative 
research that seeks to identify and describe patterns or themes within data.  This method has been 
widely used in a variety of disciplines to identify quantitative patterns, experiences, meanings, 
and realities of a particular subject matter.60 A coding system is generally developed and utilized 
to describe, organize, and analyze information obtained from qualitative studies.  It allows for 
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flexibility in theoretical framework and provides detailed description of the data.  Therefore, 
thematic analysis is a useful qualitative methodology to identify perceived barriers to research 
participation and interpret the impacts on families.  Characterization of this information can help 
direct research strategies, improve research protocols, and assist with recruitment efforts.12   
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4.0  DESIGN AND METHODS 
This project was developed from an approved and funded research study, “Strategies for 
Engaging the Duchenne Muscular Dystrophy (DMD) Community in Research.”  The study was 
designed and organized to additionally serve as a Master’s thesis project.  This project will focus 
specifically on the barriers to research participation and the familial impacts elicited solely from 
the parent-centered focus groups. 
4.1 PERSONAL DISCLOSURE STATEMENT 
As one of the project researchers and author of the present study, I wish to disclose my personal 
experiences and relationship to DMD that may bring personal bias to the study.  My training and 
experiences with DMD enhance my knowledge, awareness, and sensitivity to the topics 
discussed in the current study.  Serving as a genetic counselor and advocate within the DMD 
community, I am drawn toward the families and the medical, psychosocial, and familial 
implications associated with this devastating disease.  My role as a genetic counselor allows me 
the opportunity to interact with patients and their families in the DMD community and 
additionally be involved in the recruitment for research participants.  The dual role as both a 
clinician and researcher in the present study may present additional bias to interpretation and 
understanding of the data.  As the study presents perspectives solely from parents of boys/young 
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men with DMD, I recognize the importance to set aside my bias and experiences to better 
understand perspectives of the parent participants.  My personal bias may shape the 
interpretation and understanding of the data; however, reliability and validity of the data were 
checked in a number of ways that will be addressed in section 4.4, Reliability and Validity. 
4.2 STRATEGIES FOR ENGAGING THE DMD COMMUNITY IN RESEARCH 
“Strategies for Engaging the DMD Community in Research” is a study funded by the Foundation 
to Eradicate Duchenne (FED).  The study aimed to understand barriers to engaging the DMD 
community in research and to develop strategies to assist with recruitment efforts through parent-
centered and researcher/clinician-centered focus groups.  The study was reviewed and approved 
by the University of Pittsburgh’s Institutional Review Board (IRB) on March 5, 2014 and was 
renewed for data analysis on February 5, 2015 (Appendix A).  For purposes of this project, 
design and methods for researcher/clinician-centered focus groups will not be discussed. 
4.2.1 Participant Recruitment 
Participants were recruited in collaboration with the Cooperative International Neuromuscular 
Research Group (CINRG) and associated Muscular Dystrophy Association (MDA) clinics.  
CINRG serves as an academic clinical network for research studies in neuromuscular diseases 
with a main focus on DMD and BMD.  CINRG is an international collaborative group with over 
24 neuromuscular referral centers that each individually care for over 100 DMD patients or 
more.  MDA is a nonprofit organization that funds research, provides comprehensive care and 
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support to families, and serves as an advocate for the neuromuscular disease community.  MDA 
maintains roughly 200 specialized clinics within the United States and Puerto Rico, which 
consist of a multidisciplinary healthcare team of specialists dedicated to providing care and 
support resources to patients and their families. 
 Five CINRG sites with associated MDA clinics were selected to geographically represent 
varying patient populations throughout the United States and included the following sites: 
Pittsburgh, PA; Washington, DC; Minneapolis, MN; Houston, TX; and Sacramento, CA.  Each 
participating CINRG/MDA clinical site agreed to participate and provided a letter of support to 
demonstrate willingness to contribute recruitment assistance, facility access for focus group 
sessions, and additional guidance to research investigators (Appendix B).  The study recruited 
parents of boys and young men diagnosed with DMD for parent-centered focus groups.  Both 
families who were currently or had previously been involved in research and families who had 
never been involved in research in DMD were asked to participate. 
An IRB approved recruitment flyer was created and emailed to each clinic/research team 
to be distributed to families (Appendix C).  Flyers were posted and/or handed out at clinic visits 
and some centers utilized site-specific patient registries to contact families directly.  The 
recruitment flyer was also shared by MDA representatives and other parent advocates by word of 
mouth, email, and social media.  Parents interested in participating were asked to contact the 
principal investigator and/or the study coordinator regarding additional information and to 
confirm their son(s) had a diagnosis of DMD.  Additionally, participants were emailed a copy of 
the consent form in advance to review (Appendix D).  The study’s lead investigator obtained 
informed consent from each participant prior to commencing the focus group sessions. 
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4.2.2 Focus Groups 
Focus groups were selected as the most appropriate method to encourage exchange of participant 
thoughts and experiences, permit researcher and participant interaction, capture comprehensive 
and multidimensional responses, account for diverse patterns of participant attitudes and 
motives, and provide the most rapid and efficient collection of data.61 Focus group guides were 
developed by study investigators to facilitate conversation amongst participants and to maintain 
organization of the focus group sessions (Appendix E).  Focus groups were completed at all five 
participating clinical sites and were conducted between July and October 2014.  Three study 
investigators traveled to each site and coordinated focus groups sessions with assistance from the 
associated CINRG/MDA clinic team.  For participant convenience, focus groups were mainly 
held in conference meeting rooms at centrally located hotels that were in close proximity to the 
clinic site.  Participants received a complementary meal served prior to the initiation of each 
focus group, received remuneration of $25 for participation, and also received travel 
reimbursement up to $60.  Childcare was provided to make participation more convenient for 
parents and allowed the opportunity for parents to discuss their children without them present 
during the focus group sessions.  Children received a complementary meal and were supervised 
in a separate room by either genetic counseling students, MDA representatives, or a volunteer 
from the associated CINRG/MDA clinic team. 
Each focus group session was limited to no more than six parents of boys or young men 
with DMD in effort to ensure contribution of each participant and to maintain quality control of 
the audio transcription process.  The study aimed to conduct two separate parent-centered focus 
groups at each site including one session for families involved in research studies and another 
session for families not involved in research studies.  Each focus group was led by a trained 
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focus group moderator and lasted about 90 to 120 minutes.  The study investigators took field 
notes during each focus group and debriefing sessions were held after each focus group.  
Theoretical saturation was achieved through eight in-depth focus groups conducted with a total 
of 28 parent participants. 
Following each focus group session, participants were asked to complete a demographic 
form to depict socio-demographic factors and to provide a clinical depiction of their son(s) 
(Appendix F).  All focus groups were audio recorded and professionally transcribed by 
Landmark Associates, Inc.  A professional transcriptionist transcribed the audiotapes from focus 
groups verbatim into Microsoft Word documents.  Following review of the written documents, 
personal identifiers were removed and audio recordings were disposed of in accordance with 
IRB protocol in effort to protect participant confidentiality. 
4.3 THEMATIC ANALYSIS 
Thematic analysis is a method used to encode qualitative information, which seeks to identify 
and describe patterns or themes within qualitative research data.  Thematic analysis was 
determined as the most suitable method for data analysis given its flexibility and usefulness to 
characterize patterns of meaning across different theoretical frameworks, and provide a 
representative account of the dataset and responses to focus group questions.  Although thematic 
analysis is a widely used analytical method, its methodology is open to researcher interpretation 
and allows for a variety of approaches.12  
Themes and patterns are typically identified in two primary ways through either a 
deductive or inductive approach.  Deductive thematic analysis is a theory-driven approach in 
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which themes are derived from preconceptions or a pre-existing framework.  This type of 
approach tends to focus on pre-determined aspects designated prior to data analysis and is 
generally less descriptive of the data overall.62 Inductive thematic analysis is a data-driven 
approach in which themes are strongly linked to the data and not forced to fit within a pre-
existing framework.60 This approach has been well documented within the literature and was 
selected as the most appropriate approach for the present study in that it allowed unexpected 
themes to emerge.  In this approach, participants were permitted to freely tell their stories, which 
could potentially uncover themes that would not have been determined prior to the study.   
Braun and Clarke proposed a step-by-step process for thematic analysis.  These steps 
were used in the present study and outlined below.12 
4.3.1 Familiarization with the Data 
In order to become familiar with the dataset, all transcripts were read through at least twice 
before the coding process.  Meticulous reading and re-reading of the transcripts allowed the 
researcher(s) to become immersed with the content of the data.  Preliminary notes were taken in 
order to search for meaning and patterns across the dataset, and permitted the researcher(s) to 
collect ideas for potential codes.12 
4.3.2 Coding 
After familiarization with the data, the next step involved the coding process to generate an 
initial list of reoccurring patterns and description of the data.  Coding is a part of the analytic 
process that describes and organizes meaningful data as it relates to the phenomena and/or 
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research questions.63 A code is defined as a label that describes the data and can further be 
categorized into themes.  As the present study utilized inductive thematic analysis, coding was 
dependent on data-driven themes and encouraged the researcher(s) to remain open to all possible 
interpretations across the dataset.   
Researchers may select to manually code the data or use a software program.  Software 
programs are typically used for coding large amounts of data. For the present study, manual 
coding was selected as the best method given the dataset was easily manageable and additional 
training would be required in order to utilize a software program. Braun and Clarke suggested 
‘no data set is without contradiction’ and data may be uncoded or coded multiple times.  
Therefore, data was coded inclusively and included as many potential themes and patterns as 
possible.12 Boyatzi proposed that a good code should have five main elements: 1) a label, 2) a 
definition or characteristic establishing the theme, 3) a description to assist with flagging the 
theme, 4) a list of qualifications to identify the theme, and 5) a set of positive and negative 
examples to eliminate possible theme confusion.60 These elements were utilized to complete 
line-by-line coding to identify important components, which captured the qualitative richness of 
the data.64 Participants would occasionally attempt to incorporate multiple components into a 
single conversation segment, jump between a variety of topics, and/or lose their train of thought. 
Therefore, line-by-line coding ensured that all aspects of the data were considered and 
minimized exclusion of important components. 
A variety of approaches may be used in the coding process to ensure validity and 
appropriate coding.64 Data was coded initially through a memo writing process in which notes 
were taken directly onto printed transcripts in order to document the researcher’s thoughts 
regarding possible patterns and themes. Transcripts were then highlighted and color-coded in 
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Microsoft Word to further indicate and distinguish potential patterns before being synthesized 
into themes.  The memo writing, highlighting, and color-coding approach was performed as part 
of the coding process and continued throughout the identification of themes. 
4.3.3 Theme Identification 
Theme identification is an interpretative analytic process in which themes are developed from 
generated codes and patterns among codes.60 A theme seeks to capture an important element of 
the data related to the specific research questions and represents meaning within the dataset. A 
theme can be identified as a direct observation or as an underlying phenomenon of the data.12  In 
the present study, themes were generated inductively and strongly linked to the original dataset.  
The flexibility of thematic analysis allowed for a variety of approaches to determine themes.  
However, development of an organized system to categorize potential themes and maintaining 
consistency in identifying themes was important to ensure the data was interpreted within the 
appropriate framework. 60 Potential themes were initially noted throughout the coding process.  
Relationships between the codes and preliminary themes were considered and additionally noted 
in the dataset.  Codes and patterns among codes were grouped into potential themes and 
subthemes based on the context.  Codes were organized into preliminary themes, with some 
being classified into multiple themes. Categorizing codes into themes included a process of 
varying methods.  Utilizing a combination of methods to identify themes increased the accuracy 
of understanding and interpretation of the dataset.  
 36 
4.3.3.1 Pawing Through the Data 
One method included ‘pawing’ through the data to highlight key phrases and potential themes.65 
Specific elements within the dataset were considered when identifying themes.  Repetition of a 
particular concept was a good indicator of a potential theme.  Analogies and/or metaphors used 
by participants were good descriptors of their thoughts and experiences, and indicated a possible 
underlying theme.66 Natural transitions of content within the dataset were markers for a new 
emerging theme. Making systematic comparisons across the data focused the researcher on 
details of the information in order to better detect themes.67 Searching for theme-related material 
such as, identifying how participants perceived barriers, explained certain behaviors and motives 
that generated potential themes.68 
4.3.3.2 Color-Coding and Sorting 
After sorting through the data, a variation of the cutting and sorting technique, described by 
Lincoln and Guba, was used. In the cutting and sorting technique, important quotes or 
expressions are cut out and sorted into theme piles.  Each pile contains quotes of similar context 
and is representative of a particular theme.69 The cutting and sorting method appeared applicable 
to the present study as it created a way to compare quotes across the different focus groups sites.  
In effort to be environmental friendly and limit the amount of paper used for the current project, 
a similar method was developed and employed. 
Microsoft Word was used as a tool to highlight and pull out important quotes within the 
data.  This technique substituted the cutting out of quotes.  Highlighted quotes were then color-
coded based on its context and the potential theme.  For example, all quotes referencing travel 
were color-coded green, and all quotes referencing resources were color-coded red.  This process 
was carried out until all quotes were color-coded. A color-code guide was created in order to 
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keep record of what potential theme each color represented.  The quotes were then sorted based 
on the assigned color.  This technique was similar to sorting quotes into theme piles.  To the 
researcher’s knowledge, this variation of the cutting and sorting method has not been previously 
published within the literature. 
4.3.3.3 Key Words in Context 
Word lists and key words in context is a technique evolved from the theory: ‘If you want to 
understand what people are talking about, look closely at the words they use.’65 In the present 
study, keywords and phrases were identified in effort to count their occurrence across the dataset.  
This method was selected as a rapidly efficient technique to identify additional themes.65 All 
transcripts were merged together into one Microsoft Word document to simplify the word search 
process.  A list of keywords and preliminary themes, documented in previous notes, were used to 
complete a word search to identify instances in which a particular word or phrase occurred.  
These quotes were then copied and sorted into similar theme piles as described in the color-
coding and sorting technique.  This method was used to ensure important quotes were not missed 
and valuable concepts were not overlooked.  
4.3.4 Review of Themes 
The review of themes phase allowed for expansion and revision of candidate themes.  Each 
theme and its relevant data were reviewed and discussed amongst the research team. Potential 
themes were checked against the dataset to determine appropriate relation to the data. Continued 
review of the data permitted codes to be reorganized into different themes that may be better 
representative of the data context.  In effort to piece together interesting aspects of the data, 
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connections were made between overlapping themes and deviations between the coded data were 
identified.  Several themes that appeared to be completely separate themes collapsed into one 
cohesive theme, while other themes were divided to form two different themes.  A few themes 
did not have enough supporting data and were then discarded.  After the initial review and 
reorganization of themes, notes and thematic maps were used to help visualize connections 
between themes and to convey the story of the dataset.12 
4.3.5 Defining Themes 
The scope of each theme was defined and refined in order to further develop the story of each 
theme.  To ensure no overlap between themes, consideration was given to assess the connections 
between the story of each theme and the overarching story portrayed by the study participants as 
it related to the research questions.  During the refinement process, sub-themes were identified in 
order to provide structure to more complex themes.  Identified themes were approved and agreed 
upon by all researchers to ensure validity and appropriateness of each theme.  After themes were 
more clearly refined, names were assigned to represent meanings of each theme.12 
4.3.6 Final Analysis 
In the final phase of the thematic analysis, vivid extracts were selected that provided meaningful 
contributions in relation to the research questions and captured the essence of the dataset.  
Enough data extracts were selected to demonstrate the prevalence of each theme.  Prevalence of 
an individual theme was determined at the level of each participant.  Data extracts were 
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embedded into the analytical narrative in order to illustrate the story conveyed by the study 
participants.   
As multiple themes were identified in the FED study, Strategies for Engaging the DMD 
Community in Research, one major theme titled, Barriers, was selected to be the focus of the 
present study.  The selected theme and its associated sub-themes will be discussed in the results 
section.12 
4.4 RELIABILITY AND VALIDITY 
Reliability and validity are important concepts in qualitative research to assess both the 
objectivity and credibility of the research.  Validity refers to the extent to which research 
findings accurately correspond to the phenomenon they intend to represent.  Reliability refers the 
consistency and reproducibility of the research data.70 A number of techniques can be used to 
substantiate reliability and validity of the data.69 Triangulation refers to the use of two or more 
methods to study a phenomenon.71 Three researchers were involved with the data analysis and 
utilized a number of methodologies to identify potential themes.  To strengthen the reliability of 
the research findings, the researchers held multiple meetings to discuss the data and came to a 
consensus on identified themes.72 Additionally, study information was consolidated and sent to 
participants for review as part of a data checking method.69 This allowed participants to provide 
feedback or comments if they felt the information and presented themes were not a correct 
representation.  Participants that responded provided positive feedback and no participants 
reported a disagreement with the presented information.   
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A Cohen’s kappa was calculated as a final technique used to substantiate reliability and 
validity of the data.  A Cohen’s kappa is a statistical measure of the degree of agreement between 
independent researchers and assesses inter-rater reliability.73 Inter-rater agreement can provide 
further confidence that appropriate themes have been identified.  All three researchers were 
blinded and provided individual scores for each theme. 
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5.0  RESULTS 
Although participants were initially recruited based on whether their family had participated in 
research in DMD or whether their family had never participated in research in DMD, results of 
the study were determined to represent collective perspectives from all parent-centered focus 
groups and were not separated based on status of research participation.  
5.1 DEMOGRAPHICS 
5.1.1 Parent Demographics 
A total of eight parent-centered focus groups were conducted with a total of 28 parent 
participants of boys and young men with DMD (Table 1).  The majority of participants were 
female (68%); between the ages of 30 and 55 years old (79%); and identified as Caucasian/White 
(82%).  Most participants were from a suburban area (59%); reported a household income 
greater than $100,000 (48%); and had at least a four-year college degree (50%).  When asked 
about marital status, a majority of participants were married or in a long-term committed 
relationship (89%).   
Most participants indicated they were the biological mother of a son(s) with DMD (54%) 
and had only one child with DMD (82%).  However, two participants (7%) identified as the 
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adoptive mother of a son with DMD and two participants (7%) identified their relation to DMD 
as other (partner of a parent).  When asked to discuss whether their family had been involved in 
research, the majority of participants had participated in some form of research (82%).  
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Table 1. Participant Demographics 
Parent demographics n (%), n=28 








< 30  


























Household income * 
< $50,000 







High school or less 
College or technical school 


































5.1.2 Demographics of Son(s) with DMD 
Additional demographics were collected regarding each participant’s son(s) with DMD (Table 
2).  As discussed previously, most participants had only one child with DMD; however, two 
participants each had two children with DMD.  The 28 parent participants reported demographics 
on a total of 30 boys and young men with DMD.  The majority of the participants’ sons were 
under the age of 18 years old (87%) and required the use of a wheelchair both indoors and 
outdoors (43%).  Reported diagnoses of other conditions, aside from DMD, consisted of learning 
disabilities (20%), autism (17%), developmental delays (10%), and speech disorders (7%).  
Other diagnosed conditions reported in only one individual each (3%), included anxiety, 
cardiomyopathy, type II diabetes, hypothyroidism, osteoporosis, beta thalassemia, and Gilbert 
syndrome. 
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Table 2. Parent Reported Demographics of Son(s) with DMD 
Demographics of son(s) with DMD n (%), n=30 
Age (years) 
< 10 







Walks independently for long distances (more than a football field) 
Walks independently for short distances (around the house/one-block outside) 
Walks independently indoors but needs wheelchair for outdoors/long distances 






























5.2 BARRIERS OF RESEARCH PARTICIPATION 
As indicated in the focus group guides, participants were directly asked about barriers they face 
and their perceived limitations to participation in research in DMD.  Participants discussed 
circumstances and components, which have previously, or may potentially, deter them from 
research participation.   Participants also conversed about areas in DMD research that presented 
challenges to their families and areas in which they personally felt needed to be improved.  
Participants clearly articulated many barriers faced by families when asked to participate in 
research.  For the current study, barriers and limitations to research participation were identified 
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and organized into the following three main sub-themes: 1) commitments; 2) fighting a new 
battle; and 3) the gamble.  Prevalence of each sub-theme was determined at the level of each 
participant (Table 3).  An inter-rater reliability analysis using the Kappa statistic was performed 
to determine consistency among raters. An almost perfect inter-rater reliability for the raters was 
found to be Kappa = 0.96 (p <.0.001), 95% CI (0.937, 0.989). 
 
 
Table 3. Prevalence of Identified Barriers 






















Most participants (93%) concurred that participating in DMD research is a major commitment.  
Research participation required commitments from all aspects of families’ lives and to some, felt 
like a full-time job in and of itself.  Participants described their experiences with research 
participation being a significant time commitment and consequently forced many parents to take 
off work.  One mother stated, “We don’t always have time, because that’s the main thing, when 
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you do research, is to be able to have the time to take off if you’re working.”  Many families 
mentioned they lived paycheck to paycheck and did not have the funds or extra time at work to 
take off in order to travel to research centers.  One parent stated, “…how am I supposed to 
engage and invest all that time, energy, and that means money, because any day that I’m not at 
works means I’m not earning.”  The decision to participate in research left many parents 
concerned about risking their job and main source of family income.   
Parents who were fortunate to have jobs that allowed them the opportunities to take time 
off work and travel to research centers, were still imposed with travel commitments.  One father 
discussed travel concerns that were echoed by other participants, “I feel like, financially…you’re 
using all of your PTO, your extra time at work to travel…Time commitment.”  Travel 
commitments are another challenge mentioned by many participants, which strained their ability 
to participate in research.  One mother claimed, “…when we first started the study…our biggest 
thing, at the time, we didn’t have a vehicle, so we had to take the bus.  Those long days…we had 
to really commit to literally going from 8:00 in the morning until 6:00 at night.”  As a majority 
of the participants’ sons required the use of a wheelchair, several families discussed the 
difficulties of traveling with a child with a disability.  Many participants expressed their 
frustration of transporting a power wheelchair in both their family car and on an airplane.   
Additionally, participants referenced geographical location and proximity to research 
centers as factors influencing their decisions to participate in research.  Many participants shared 
the same feelings as one mother, “I think I checked into a study at one time when he was younger 
and it was the travel deal.  It was so far away and you had to go and be there awhile.”  
Participants living in rural areas or areas in which research centers are scarce, felt they needed to 
make a greater commitment than those living in urban or suburban areas that are more 
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conveniently located to research centers.  One mother expressed, “It’s the luck of the draw, 
where you live, as to whether or not you get to participate in a study.  That’s frustrating.” 
As taking time out and traveling to participate in research imposed multiple stressors on 
the parents, it was also suggested that the commitments could create challenges for their sons 
with DMD.  One mother stated: 
Another area was time.  As my son was younger, it was easier to get him to and from 
things, take him out of school, work around activities.  As he’s progressed to high school 
and now to college, there’s just not the time to do three or four visits to taking him out of 
school.  Where there’s a bigger impact at a high school or a college level than there is at 
an elementary school level.  Depending on the age of the child and the extent of the study. 
Other parents discussed concern with research commitments limiting their sons from attending 
other appointments crucial to their sons’ well being.  One mother discussed unexpected 
circumstances, which posed additional challenges, “We've had circumstances…where we weren't 
prepared to stay the night.  We weren't prepared to have separate visits, so we had to cancel 
school.  We had to cancel therapy.  I had to cancel his IEP meeting.  Things like that make it 
very difficult.” 
5.2.2 Fighting a New Battle 
In addition to parents feeling research required major commitments from families, a majority of 
participants (93%) also perceived research participation as frustrating and added another layer of 
stress and worry to the overwhelming emotions that participants were already experiencing with 
the diagnosis of DMD alone.  A majority of participants felt participating in research was 
equivalent to fighting a new battle in DMD.  One mother provided her perspective, “I think what 
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it comes down to is Duchenne families have such a large amount on their plate.  The study 
becomes a new battle to fight.  I look at Duchenne like dealing with a toddler.  You have to 
choose your battles.”  Participants discussed the daily challenges associated with DMD and how 
those challenges may deter them from participating in research.  Many participants admitted they 
were overwhelmed and uneducated about DMD and that they placed all their trust in their 
healthcare providers to inform them of research opportunities.  One mother stated, “We're not 
educated on how that [research] works.  We just put all of our faith and trust into our doctors 
and our genetic counselors that we're hooked up with. Why, you ask?  Because it is so 
overwhelming just to live with this each day…” Therefore, participants claimed that if they were 
not informed of research in clinic, then they were not seeking research opportunities for their 
sons.  Many participants professed they were never introduced to research while in clinic, “I 
can't tell you how many times I've been to clinic and not one time, I've been told about a trial.  
Not once, and I've been to many clinics.”  These participants felt deprived of the opportunity to 
participate in research and to also learn more about the research process.  
Additionally, participants were not receiving appropriate resources and educational 
materials that they felt should be provided by the healthcare team in clinic.  Participants claimed 
they were confused about the research process, uneducated, and did not know the appropriate 
questions to ask about research.  One mother mentioned, “Yeah, but if you’ve got a parent who’s 
sitting there, who’s totally devastated with their child, and not knowing what to do, and then not 
educated enough—I’m sorry.  I’m not trying to say anybody’s stupid.  I’m just saying they’re not 
educated to say, ‘What can I do for my son?’”  Participants expressed feeling lost and did not 
know where and how to access resources associated with research in DMD.  Finding and 
receiving appropriate resources became another battle for parents to fight.  One mother stated, “I 
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don't know these resources, until this comes along, where we’re actually sitting down.  I’ve got 
about ten things that have been told to me that I was like, “Well, I didn’t even know to ask.”  I 
don't know who to go to for.”  In addition to lack of resources, participants felt they were not 
receiving enough encouragement and support to participate in research.  One participant stated, 
“What can you do for the moms and the kids who can't, and really need to be a part of these 
studies to save their life and to save others?  They don’t have the resources and they don’t have 
the support.”   
Race/ethnicity and socioeconomic status were also mentioned by several participants as 
being a significant determinant of whether families received access to appropriate resources and 
research opportunities.   One mother described challenges for non-English speaking families in 
her community: 
… we have a lot of non-English-speaking families.  They're not involved in any trials 
because they don't get the information correctly.  They just don't get information, period.  
They don't have the funds to even have a computer to even know that this exists.  They 
just don't have the resources. 
One father mentioned his frustration as a Hispanic individual, “When I go to the clinic, I see two, 
three, four, even nine more patients that speak nothing but Spanish.  If it wasn't for [our MDA 
representative], that connection would be lost.  As far as studies or information in Spanish, 
none.”  Another mother discussed her first-hand experiences as a woman of color and touched 
on barriers in which minority groups are faced with: 
The issue for research for people of color is that we’re not always involved in these 
things.  We don’t always get access.  We don’t always get information. Most people of 
 51 
color are not wealthy.  They do not have the funds.  You have to have education in order 
to be able to make informed decisions. 
As most participants felt uneducated on the essence of research, participants admitted 
they had to educate themselves on research in DMD.  Participants were overwhelmed and did not 
understand what research their son qualified for.  The sheer complexity of research and sifting 
through research eligibility criteria became another battle in which parents faced.  One 
participant stated, “Understanding some of these other studies that are going on, it’s become 
very knowledge intensive.  There’s confusion as to what do I qualify for?  What would help my 
son?”  Most participants felt the study eligibility criteria are too strict and immediately 
prohibited their sons from participating in research.  One mother described her experiences, 
“Other studies, we haven't done cuz our oldest is nonambulatory, and our youngest doesn't take 
prednisone, so that cuts us out of every trial, basically…I think the criteria are too strict.”  Many 
participants whose sons were non-ambulatory concurred and felt a loss of hope persuading them 
not to participate.  One mother stated, “I think there’s probably a big drop-off once your child is 
no longer ambulatory, where there’s a sense of loss of hope.”  These participants felt as though 
they had lost the research battle and that there were no research opportunities left for their sons 
to participate in.  
5.2.3 The Gamble 
Participants expressed concern regarding perceived risks associated with research participation.  
A majority of participants (86%) felt that associated risks and fears placed families in a realm of 
the unknown in which they in essence, were taking a gamble on research and their sons.   Parents 
described being forced to enter into a decision making process in which the benefits of research 
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participation must be weighed against the risks and factors that are out of the families’ control.  
An invasive procedure involved in research was a major determining factor that many 
participants claimed persuaded them not to participate.  One mother described her feelings: 
 I think some of the decision-making that we, as a family, have gone through partly has to 
do with how invasive the test is.  There were some tests that we were—or some pilots or 
studies where it was gonna require them to go in and take a muscle out.  As my son was 
progressing from walking to non-walking, we had to evaluate would this—how would this 
impede his healing process, his ability to continue to walk, to continue to have 
functionality?  Would there be loss of functionality due to the invasiveness of the study 
that was going forward? 
Although invasive procedures concerned parents, participants also mentioned how terrified their 
sons were of undergoing an invasive test.  Many parents stated that their sons were at an age in 
which their opinion on research mattered and was ultimately the deciding factor as to whether 
their family participated in research.  Several participants felt participating in research deprived 
their son of a “normal life.”  One mother described the gamble their family faced between letting 
their son live a somewhat “normal life” versus having him participate in a research study that 
may increase his quality of life, “…it’s more of a pain or an obligation or something I’ll do for 
mom…—he sees himself as normal…when he comes and does a study, or he does something, it 
points out his differences.  It points out his disabilities…” 
Participants discussed a level of uncertainty associated with research participation.  This 
uncertainty left many participants to question research participation and if it is really the right 
decision.  Along with a level of uncertainty expressed by participants, came concerns for safety 
and unspecified side effects that may be associated with a particular research intervention.  
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Participants discussed many uncertainties associated with participation in research studies.  One 
mother described her battle between weighing the risks and benefits, “For us, we've 
contemplated the whole risk over the benefit, and what's more important, quality or quantity for 
us?  It's a battle.”  Many participants discussed fear of the unknown consequences, risks, and 
even benefits when pursuing participation in research in DMD.  One mother mentioned, “It 
would scare me.  I would need to know the side effects…I would need some type of information 
in front of me to make that educated decision to say, ‘Okay, is this worth a risk or not?’” 
When considering the benefits and risks to research participation, several participants saw 
an immense level of benefit to particular drug trials, such as exon-skipping trials.  Therefore, 
many participants felt the possibility of being assigned to a placebo was too much of a gamble 
and elected not to pursue participation in research.  One mother expressed: 
They see that placebo, and they don't want to take the chance of being on that placebo to 
be excluded.  That's a huge factor.  I think placebo is one of the main reasons why many 
people just don't do it.  Why take that risk? In my opinion, I honestly think in Duchenne, 
since it is a rare disease, placebos should not exist…I think for Duchenne, they don't 
have time.  I think it's really a waste of time. 
Several participants stated they would consider enrolling their son in research if his participation 
would not impact his eligibility for other research opportunities.  One mother attested to this 
viewpoint echoed by many participants, “Let's say it's something that could help his strength and 
we know it wouldn't impact his eligibility for [another drug trial]…we would probably consider 
it.”  However, other participants felt it was too much of a gamble to risk enrolling their son in a 
research study at the cost of potentially becoming ineligible for another, more desirable study.  
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One mother claimed. “So I guess there is one that I chose not to pursue, and the reason I chose 
not to pursue it is because I was holding out for the exon-skipping study.” 
The notion of “holding out” was expressed by participants in the majority of the focus 
group sessions.  Participants felt they had received insightful knowledge regarding which 
research studies were perceived as most successful within the DMD community.  The perceived 
promising studies were appealing to most families and participants admitted to declining on 
available research opportunities to wait for a better research opportunity.  One mother stated 
“…We have been told he will be in trial within a year, and probably getting this.  Yes, we wanna 
participate but we will hold off until we get that.  Because we have seen the research, and we 
know what it's doing.  We know it will keep him alive.”  Another mother further elaborated on 
this notion and described the gamble that many participants may take: 
I guess, too, when you hear about something in particular that you’ve put so much hope 
in and that you think has so much promise—especially like the exon skipping—you kind 
of put that at the top and then you filter everything else based on how it’ll affect our 
ability to get into that or what it’ll affect if that comes along.  I think a lot of the gamble 
we take and the decisions that we make are based on what we feel the most hope for 
going forward. 
5.3 IMPACT OF RESEARCH BARRIERS ON FAMILIES 
As participants discussed barriers they faced and perceived limitations to participating in DMD 
research, families also alluded to theses barriers having significant impacts on their families.  
These impacts placed additional strains on families and also appeared to play a pivotal role in the 
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family’s decision to enroll in research studies.  One mother shared an opinion echoed by many 
participants, “…because my son deserves—each one of my children deserve to live life in joy.  I 
don't wanna do it [research] at a cost where it all passes by, and my family has nothing.”   
Almost all participants discussed various impacts on their families as a result of 
participating in research studies and/or due to barriers prohibiting them from participating.  One 
mother outlined the many aspects of families’ lives that can be impacted: 
We have sacrificed family vacations.  We have sacrificed birthday parties. We have 
sacrificed my job. I had to quit my job. I want to say just in the past three weeks for 
different studies, we've traveled, I don't know, 2,000 miles? …We've put a lot of miles on 
our car. We've had to get another new car because we put so many miles on our other 
car. My husband basically works just to get us through appointments, medication, and 
studies. Financially, it takes a toll.  
Participants described financial burdens, sacrifices, and psychological stress that families endure 
in order to overcome barriers and limitations they face when asked to participate in research. 
5.3.1 Financial Burden 
Most participants agreed that participating in research posed a financial burden to families.  
Participants discussed the financial challenges, which limited them from participating in 
research.  Several participants claimed they would be jeopardizing their job in order to 
participate in research.  One mother expressed, “… we have really to weigh the pros and 
cons…You have to make sure that you can afford to leave for work.  You may not get paid for it, 
for a leave.  Will your job be there when you get back? One mother expressed how many 
families living paycheck-to-paycheck struggled just to provide for their son’s disability and 
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having to take off work in order to participate in research was just another financial challenge 
placed on families.  She stated: 
..we needed a handicapped van, we bought a handicapped van.  We needed a 
handicapped house, we moved to a handicapped house.  We were able to do things for my 
son, but there are other families that don’t have that…If you have a family where people 
are just regular people and they’re dependent on every penny, and they live from 
paycheck to paycheck, then it’s kind of hard. 
Some participants greatly relied on two incomes to provide for their family.  However, several 
participants discussed concerns for one parent having to give up his or her job in order to cover 
responsibilities associated with research participation.   
Several participants mentioned their families had considered relocating to areas closer to 
research centers in order to get their son involved in research.  However, participants also 
discussed the major financial burden associated with relocating their family.  One mother 
described a discussion she had with her husband in relation to potentially relocating to Europe: 
I mean we have thought about, “Well, what if we move to Europe and he could actually 
get this drug?” But then of course the financial burden came up because we can’t just 
pick our family up and move to Europe and my husband would be able to get a job to be 
able to support our family.  My husband had made the comment, like, “Well, I would 
have to stay here with our daughter and you would have to go and take [our son] for a 
year.” 
This participant alluded to an important topic discussed by other participants and the various 
sacrifices that families must account for when considering to enroll in a research study. 
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5.3.2 Family Sacrifices 
The majority of participants discussed strains placed on their families when asked to participate 
in research in DMD.  Participants reported making many sacrifices in order to take part in 
research studies.  Participants discussed the commitments required to participate in research and 
how those commitments have taken away from their time spent with family.  One mother 
expressed her thoughts, “I'm thinking, what the heck am I doing?  This is taking my valuable 
time, our precious short time we have together, away from my family.”  One mother explained 
that the research visits became their family vacation and was not something their family enjoyed:  
Because really, I’d like to take a vacation to Hawaii or something with my family, rather 
than spend all the time—I spent the last 10, 11 years going [for research]. That’s been 
my biggest vacation trip.  Duchenne is important, and to change the course of it, but 
that’s not necessarily what my family’s enjoyed.  
Families considered the time they have with their son and each other, to be precious and 
valuable.  One participant questioned, “That’s when I start to think, ‘Why am I here?  Why am I 
here?  I should be out at the park, with my son, because how many of these days am I gonna 
have?’ That becomes frustrating.”  Participants described making shifts in their daily lives in 
order to accommodate for participating in research.  These shifts in their daily lives were 
reported to have significant impacts on their loved ones.  Many participants expressed concern 
for their unaffected children.  One mother stated, “…because I have two other kids.  That is one 
of my big things.  I don't want them to feel like they're off to a side for possibly a year while I'm 
just focused on [son with DMD].”  Despite the best effort of parents to not appear as though they 
are giving all their attention to their son with DMD, many participants admitted that siblings 
often felt neglected.  One mother claimed: 
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Siblings have often felt like they’re forgotten…Our son is the youngest of our three.  I 
know, with my own children, sometimes they’ll be like, “I’m right here.  You never 
listen.”  It’s like, “I do hear you, and I am multitasking…They feel, because you focus so 
much on the weakest one that they’re forgotten.  It’s, again, striking that balance. 
In addition to impacts on siblings, participants also discussed impacts and strains on their 
marriage and committed relationships.  One mother stated, “If you are lucky enough, fortunate 
enough to still be married, because many, by the way, are divorced…you're losing your better 
half… Are you strong enough to go do that alone with your Duchenne son?  I don’t know if I 
would be.” Though most participants were either married or in a committed relationship, several 
participants discussed experiences of single parents in the DMD community and the 
overwhelming commitments they are faced with, limiting their participation in research, “When 
you're a single mom or you don’t have time, you don’t have money, you have other kids, you 
have other commitments.”  Participants also mentioned consequential split parenting as a result 
of choosing to relocate to provide their son with more research opportunities.  One mother stated, 
“Then usually, it's just one of the parents that goes [to research visits] because both parents 
can't take time off.  One has to stay with the other [children].”   
5.3.3 Psychological Stress 
Many participants discussed challenges to managing study participation as a result of 
psychological stress associated with the many barriers to participating in research in DMD.  
Parents shared how they are already overwhelmed by DMD in and of itself and mentioned that 
research contributed to an additional layer of emotional stress and frustration. One mother stated, 
“… it's our career.  It's what we do.  Our job is managing Duchenne.  We don't ever get a break 
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from it.”  Participants discussed feelings of isolation associated with a new diagnosis and how 
families who just learned that their son has DMD may be unaware of research opportunities and 
where to turn to learn about them.  One mother added, “I felt like a psycho person, very 
emotionally distraught, because it is very frustrating with research.”   
Participants conversed about mixed feelings regarding research participation.  
Participants discussed the tug of war between motivations to participate in research and the many 
barriers discouraging their participation.  One mother stated, “It’s [research] a collaborated 
team effort, but it’s also an emotional rollercoaster.  It is pay it forward.  It’s also when’s it 
gonna happen, will it happen in time, and your heart breaks for others, and it breaks for your 
own child.  It’s all of that.”  Some participants described feeling helpless and alone, particularly 
those parents in which cultural barriers played a role.  Although all of the participants spoke 
English, some participants mentioned the challenges other families in the DMD community 
faced who did not speak English.  One mother stated, “The language barrier for the families that 
are in areas that they can’t communicate, and they feel exceptionally alone because there’s 
people they can’t even talk to, to share that.”  
Additionally, participants expressed how they wanted to help their sons as much as 
possible, but were constrained if their son was unable to qualify for certain research studies.  One 
mother clearly stated, “I don’t feel like I do enough, because sometimes we feel helpless because 
there’s only so much we can do as parents.”  Several participants perceived study criteria as 
being too strict and resulted in underlying emotional turmoil and anxiety.  One mother shared her 
feelings regarding her sons’ inability to qualify for research studies: 
It is upsetting at times to see that one-in-a-million kid who fits the criteria for whatever 
study, and you see them benefiting from it.  That's definitely difficult.  I personally wish 
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that you had to be on a gag order, if you have a child in a study, that you should not be 
able to talk about it.  Because I think for some people, especially the newly diagnosed 
who haven't really understood all the processes they have to go through, that could really 
send someone, emotionally, I think, in a place that's not good…Having two boys…neither 
of them qualify for anything…It is frustrating. 
Along with the many frustrations regarding the barriers associated with research participation, 
participants also expressed increase worry and fear related to the uncertainty of research studies 
in DMD.  Participants exchanged opinions regarding their sons undergoing invasive procedures 
and also being potentially exposed to experimental drugs in which the risks are unknown.  One 
mother stated: 
I'm allowing you [researchers] to take my kid and put something in his body with the 
hope that it will help him or someone else.  Whether it's a placebo or not, I'm letting you 
fundamentally mess with my kid…With the chance that it's gonna hurt him when he 
already has a terminal disease…He's a person with a terminal illness with a short 
amount of time. 
Participants talked about challenges of trying to weigh the potential of helping their son 
and “paying it forward” versus exposing their son to pain and invasive procedures.  Participants 
discussed the benefits and desire to participate in research, but the worry and guilt felt by some 
participants weighed heavily on their decision to allow their son to participate in DMD research.  
One mother shared her feelings, “…that was the first study that we did and I was just more 
worried because they were doing a skin biopsy and just kinda felt guilty that we were inflicting 
pain on him to do the skin biopsy.  Then, too, was worried.  Will he be able to even make it 
through the whole MRI thing?  Would it scare him?   
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The level of psychological stress was not only affecting parents but according to some 
participants, also had an impact on their sons. One mother discussed the difference in how 
parents can perceive research as providing hope while their sons struggled with the emotional 
sequelae associated with research participation.  One participant stated, “We’re getting there, but 
they [boys/young men with DMD] don’t necessarily see these trials as hope, where the parents 
tend to look at them as hope.  They tend to see it as pointing out where they’re not normal.  I 
think for adult children that that’s an issue.  On the social emotional level for them.”  Several 
participants described the desire for theirs sons with DMD to be able to relate to their peers and 
lead a “normal life.”  Participants expressed how some boys and young men with DMD do not 
view research as fun and therefore, discouraged their participation.  One mother stated, “…it's 
not fun for them.  They don't wanna go, they're discouraged.  They already have enough anxiety 
in their day-to-day activities.  They just wanna feel normal and be able to relate to someone.” 
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6.0  DISCUSSION 
The present study utilized qualitative thematic analysis to identify parent perceived barriers to 
research participation and identified how those barriers may impact families in the DMD 
community.  Participating in research was shown to affect many aspects of participants’ lives 
and additionally had an impact on the entire family.  Families expressed a desire to participate in 
research studies, but not at the cost of their families.  As each family shares its own particular 
experiences and psychosocial perspectives related to research participation, a potential theory 
suggested from the data may be described as finding the right type of research study, for the right 
family, at the right time in the disease process.  These findings highlight the need for greater 
support and appropriate resources to alleviate potential barriers faced by families.  Results of the 
present study additionally identified a novel barrier to research participation and is one of the 
first studies to characterize the notion of “holding out” for a desired research study in the DMD 
community. 
6.1 BARRIERS OF RESEARCH PARTICIPATION 
Studies have been conducted to identify family perspectives, motives, barriers, and impacts of 
research participation within various disease populations, most prevalently within the cancer 
population.42 Although, studies have not focused specifically on barriers to research participation 
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within the DMD community.  In the present study, three main barriers or sub-themes were 
identified: 1) commitments; 2) fighting a new battle; and 3) the gamble.  Barriers to research 
participation identified in the present study were similar to those found within cancer 
populations.  However, parents of children diagnosed with a progressively fatal disease, such as 
DMD, face different challenges compared to children with cancer or other disease diagnoses and 
therefore, additional barriers potentially unique to DMD and rare disease populations were 
identified.43  
The barrier of “commitments” described the dedication and many commitments required 
of families to participate in research.  Most participants concurred that participating in research 
in DMD is an overall investment requiring a major commitment from all aspects of families’ 
lives.  Factors that were found to influence the decision making process for families included 
time constraints, distance and travel to study sites, and interferences with work, home, and/or 
personal responsibilities.  These barriers associated with the many commitments required to 
participate in research are similar to those that have been identified in other studies.42 
Additional time and effort, including costs and travel, have been described in the 
literature as being concerns of patients participating in research.74; 75 Results from the present 
study revealed similar findings and identified significant time commitments involved in research 
participation, which consequently forced many participants to take off work in order to travel to 
research centers.  Participants mentioned they would have to use up all their vacation days at 
work in order to maintain the travel and time commitments involved in research participation.  
Therefore, the decision to participate in research left many participants concerned about 
jeopardizing their job and main source of family income.  However, parents who were fortunate 
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to have jobs that allowed them the opportunities to take time off from work and travel to research 
centers were still imposed with travel commitments.   
Participants referenced geographical location and proximity to research centers as factors 
influencing their decisions to participate in research.  Cancer studies have also found that 
transportation barriers or distance to a clinical trial site is a limitation identified by many 
patients.75 One study comparing barriers to clinical trial participation in rural and urban 
communities in South Carolina, found that there were no significant differences in willingness to 
participate in clinical trials, but did indicate that rural residents were more likely to lack 
awareness of available research opportunities and perceived access to research sites as a 
limitation to research participation.74 Results from the present study suggested similar findings in 
that participants living in rural areas, or areas with limited research opportunities, were perceived 
to have a greater travel commitment than those living in urban or suburban areas that were more 
conveniently located to research centers.  Additionally, travel to research centers may become an 
overwhelming barrier to participation, due to physical impairments associated with DMD.39 
Many DMD studies require multiple trips to research centers, which make continuous 
involvement in research studies a difficult task for families.  Given that most participants’ sons 
required the use of a wheelchair, a majority of the participants in the present study discussed the 
difficulties of traveling with a child with a disability.  As many participants mentioned long 
hours and/or days of travel by plane, car, and bus, challenges associated with travel limited many 
families from participating in research.  Other rare disease studies have also characterized 
particularly burdensome travel commitments associated with transporting a child with a 
disabling disease.8  
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As traveling and taking time away from work to participate in research imposed multiple 
strains on the parents, it was also suggested to be a commitment for their sons with DMD and 
required some unexpected commitments.  Some studies have shown that participants struggled 
with understanding the full extent of their commitments associated with research participation, 
even when undergoing an extensive informed consent process.9 Some of these unexpected 
commitments or commitments that parents did not consider, may have a significant impact on 
their sons with DMD.  Results of the present study revealed that some boys and young men with 
DMD had to miss school and were hindered from attending other doctor appointments that were 
crucial to their well-being.  Therefore, the major commitments required of families to participate 
in research added to the overwhelming challenges that parents already experienced with the 
diagnosis of DMD alone. 
In addition to the overwhelming challenges of caring for a child with DMD, frustrations 
and multiple complex elements associated with research participation became a new battle for 
families to overcome and was described by the barrier of “fight a new battle.”  With progressive 
and life limiting disorders, such as DMD, time can be the ultimate enemy and present many 
pressures that affect the decisions of parents to involve their child in research studies.8; 39  Some 
studies have identified an inconvenience to everyday life, as a potential barrier to research 
participation in cancer clinical trials.75 Similarily, participants in the present study discussed the 
daily challenges associated with DMD and how the challenges of the disease may limit them 
from participating in research altogether.  Results showed that some participants relied on 
healthcare providers to inform them of research opportunities since families felt so 
overwhelmed.  Therefore, if participants were not informed of research opportunities while in 
clinic, then they were unaware of research opportunities for their sons and less likely to 
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participate.  Surprisingly, many participants were never introduced to research in the clinical 
setting and were forced to educate themselves on research in DMD through other means.   
Additionally, cancer studies have found that barriers to research participation included 
patients who were not informed or not given adequate information on research studies, similar to 
findings outlined in the present study.59 Some participants expressed a desire to participate in 
research, but mentioned they did not receive appropriate resources and educational materials to 
familiarize them about research opportunities.  Participants admitted they did not know the 
appropriate questions to ask and to whom they should direct their research questions.  Studies 
have shown that individuals are less likely to participate in research studies that they are 
unfamiliar with.76 These findings are similar to those identified in the present study in which 
some participants claimed they were confused about the research process and sometimes felt 
uninformed.  One study found highly educated individuals were more knowledgeable about 
participation in research.59 This may be supported in the present study as most participants were 
well-educated and active within the DMD community, which may have contributed to a better 
understanding of DMD research studies. 
As research is a topic new to many families, studies have shown that parents need 
sufficient time to ask questions, to digest information regarding research participation, and 
require adequate psychological support.77; 78 Results of the present study showed that participants 
had a lack of resources, and were not receiving enough encouragement and support to participate 
in research.  Race/ethnicity and socioeconomic status were mentioned by several participants as 
being a significant determinant of whether families received access to appropriate resources and 
research opportunities.  Though all participants spoke English, several participants identified 
with an ethnicity/race aside from Caucasian/White.  As most diagnosed cases of DMD are 
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reported in Non-Hispanic/White individuals, racial/ethnic specific prevalence has been found to 
be the highest for Hispanic individuals.79 According to the United States Census Bureau, as of 
July 1, 2013, 55% of the Hispanic population lived in California, Florida, and Texas.  
Interestingly, participants from the Houston and Sacramento focus groups sessions were most 
vocal about language and cultural barriers associated with research participation in DMD.  Other 
participants discussed racial barriers limiting African American populations from gaining access 
and information about research opportunities in DMD.  These findings highlight the urgency to 
address needs expressed by families experiencing cultural barriers to research participation and 
providing appropriate resources. 
Participants additionally felt confused and did not understand what research their son 
qualified for.  As patient registries, such as DuchenneConnect have been useful tools to notify 
patients of research opportunities, the utilization of registries was not consistently referenced by 
parents.  Participants also felt study eligibility criteria were too strict and immediately limited 
their opportunities to participate in research.  Most research in DMD desires younger study 
participants at an early disease stage and therefore, study eligibility criteria typically exclude 
most non-ambulatory individuals with DMD.6 As a majority of the participants’ sons with DMD 
were non-ambulatory, most participants felt as though there were no research opportunities left 
for their sons to participate in and felt a loss of hope when their sons were not able to qualify for 
studies.  However, those participants whose sons did qualify for research studies still felt 
participating in research was similar to taking a gamble in which families had to weigh the 
benefits and risks.  
The barrier of “the gamble” described the perceived risks and fears associated with 
research participation that families must consider when deciding whether engaging in a specific 
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research study is worth the gamble.  Weighing the benefits and risks to research participation in 
the DMD community has been previously described and one study found that families were more 
willing to accept greater risks and side effects for a disease in which there is currently no cure.  
However, the study also found that parents were not willing to expose their sons to infinite 
risks.10 One study found that factors contributing to negative research experiences, including 
pain and discomfort associated with invasive procedures, and adverse side effects related to the 
research intervention, played a significant role in determining whether families participated in 
research studies.41 The use of an invasive procedure in the present study was a major determining 
factor that persuaded some participants to not participate in research studies.  Results of the 
present study additionally found a level of uncertainty associated with research participation 
regarding concerns for safety, unknown consequences, and the potential for adverse side effects 
or loss of functionality.  Similarly, one study identified families experiencing negative emotional 
impacts due to stress associated with invasive procedures and disappointment related to their 
sons’ deterioration.7 Participants in the present study also felt pressured to allow their sons to live 
a “normal life” without multiple research visits, but were conflicted with the potential of research 
studies to increase their sons’ quality of life and provide hope.   
Due to the progressive and fatal nature of DMD, families may become acutely sensitive 
to any possible suggestion of hope for potential treatment options.  It has been documented that 
families may become vulnerable to exaggerated hope and therapeutic misconception as a result 
of high trial expectations.6; 41; 43 Results of the present study indicated that participants felt the 
possibility of being assigned to a placebo was too much of a gamble to take for a disease in 
which there is currently no cure and reduced life expectancy.  Therefore, participants felt that 
placebos were a waste of time that their sons ultimately did not have to spare.  Additionally, 
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when considering the benefits and risks to research participation, several participants saw an 
immense level of benefit to certain drug trials, such as exon-skipping trials.  The present study 
highlighted a novel barrier to research participation in which participants would hold out for a 
more desirable research study, such as exon-skipping, than to risk their son being ineligible due 
to his enrollment in what they perceived to be a less promising study.  Participants mentioned 
that the ultimate gamble regarding research in DMD is based on what will provide the most hope 
going forward. Participants admitted they would refrain from enrolling in a research study in 
order to wait for their sons’ specific mutation to be included in the study criteria for a more 
promising study. This is the only study known by the researcher to characterize the notion of 
“holding out” for better research studies in the DMD community.  Given the hype of promising 
research and active parent/advocate groups, this notion may be present in the wider DMD 
community and should further be explored. 
6.2 IMPACT OF RESEARCH BARRIERS ON FAMILIES 
Participating in DMD research can impact many aspects of families’ lives.  As participants 
discussed barriers they faced and perceived limitations to participating in research, parents also 
alluded to theses barriers having significant impacts on their families.  Challenges that families 
experienced when asked to participate in research required families to make many sacrifices 
affecting their families financially, psychologically, and structurally.  Psychosocial issues 
experienced by families were shown to potentially affect a family’s ability to fulfill the 
commitments required for research participation and presented as an additional barrier for 
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families.  The impact of research barriers on families was found to play a pivotal role in a 
family’s decision to participate in DMD research. 
Families already endure a variety of costs and loss of work hours associated with the 
diagnosis of DMD alone.56 Results of the present study found that research participation may 
present a greater loss of work hours and additional financial stress on families.  Participating in 
research was shown to be a major commitment that forced parents to take time off work in order 
to travel and fulfill research requirements.  Taking time off work may result in families suffering 
a loss of wages and consequently jeopardize their jobs.  These financial challenges and 
additional barriers associated with research participation also resulted in psychological affects on 
families. 
The diagnosis of DMD can have a multitude of affects on the entire family and result in 
many psychosocial consequences.28; 51; 52; 50 Managing the many commitments required to 
participate in research added an additional layer of emotional stress to the many challenges 
families already faced with the diagnosis of DMD alone.  Some participants described feeling 
helpless, emotionally distraught, and overall uninformed about research opportunities.  These 
emotions may be a result of families not receiving appropriate resources and support to actively 
engage in research opportunities.  Not being able to appropriately engage in research 
opportunities left many participants feeling frustrated.  Participants felt it their job, as parents, to 
do everything they can for their sons, but encountered a blockade when their sons were not 
qualifying for research studies. As participants admitted to “holding out” for mutation-specific 
research interventions, such as exon-skipping trials, families are forced to wait for the inclusion 
of their sons’ specific mutation in order to be eligible for those studies.  One study found that 
many parents associated doing nothing with accepting the fate of early death in DMD.8 In the 
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present study, the inability for participants’ sons to qualify for research studies may be 
comparable to accepting the fate of early death and resulted in a lack of hope experienced by 
some parents. 
Participants desired to have their sons participate in research as a way to “pay it forward” 
to future generations, but perceived certain aspects of research to include significant risks and 
felt an increased level of worry and guilt by allowing their sons to be exposed to a potentially 
invasive or harmful research intervention with uncertain consequences.  Guilt has been a 
common emotion parents experience with the diagnosis of DMD, but to the researcher’s 
knowledge, has not been associated with regard to their sons’ participation in research studies.79 
The potential for risks associated with research participation also had emotional impacts on 
participants’ sons.  Results of the present study found many parents perceived research as 
providing hope, while some of their sons felt research limited them from living a “normal life.” 
Some participants’ sons perceived research participation as a constant reminder of the challenges 
they face and having to miss out on things they enjoy, because their days revolve around 
research visits. 
The many psychosocial and financial implications of research participation can 
additionally impact family relationships.  Though the many commitments required of families to 
participate in research allowed parents to spend more time with their sons with DMD, results 
showed that those commitments also took away valuable family time with other family members 
and added strains on their marriage and/or commitment relationships.  Findings also showed that 
some participants felt they were neglecting their unaffected children.  Unaffected siblings in the 
DMD community have been shown to have an increased risk for emotional problems and 
rebellious behavior due to feelings of jealously, neglect, and isolation.80 Results of the present 
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study highlighted similar concerns for neglect of unaffected siblings and may suggest that 
feelings of jealousy and isolation would intensify in unaffected siblings when families elected to 
participate in DMD research. 
The present study focused solely on the barriers to research participation, with the 
purpose to highlight the impacts these barriers have on families and the need to provide support 
and resources to families to alleviate these barriers.  Families expressed a desire to participate in 
research studies, but not at the cost of their families.  Since each family shares its own particular 
experiences and psychosocial perspectives related to research participation, each family is 
impacted differently and has its own set of unique needs to be addressed.  A potentially useful 
theory may be suggested from the data and can be described as finding the right type of research 
study, for the right family, at the right time in the disease process. 
6.3 POTENTIAL IMPLICATIONS FOR GENETIC COUNSELORS 
Genetic counselors may benefit from understanding barriers families face and the impacts these 
barriers can have on patients and their families when asked to participate in DMD-related 
research.  Barriers and limitations to research participation can result in psychosocial sequelae 
impacting the entire family.  Genetic counselors play a significant role in providing psychosocial 
support to patients and their families.  Therefore, results identified in the present study may have 
potential implications for genetic counselors and other healthcare providers occupying a similar 
role. 
As defined by the National Society of Genetic Counselors (NSGC), genetic counselors 
serve as a resource to patients and their families by helping them to understand and adapt to 
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medical, familial, and psychosocial implications associated with a genetic condition.  Genetic 
counselors often play a pivotal role in communicating research opportunities to patients and their 
families.81 As many genetic counselors hold an additional position as a study coordinator with 
both clinical and research responsibilities, genetic counselors may be involved in the recruitment 
of research participants.  Therefore, genetic counselors can make the initial introduction of 
research and provide resourceful tools for families to keep them up-to-date and informed on 
research opportunities.  
Additionally, genetic counselors serve as advocates for all patients and their families 
according to their specific needs.  As barriers to research participation may be shared amongst 
families in the DMD community, barriers and limitations present in varying degrees and are 
unique to each family.  Additionally, effects of barriers and limitations to research participation 
can have divergent impacts on families.  Genetic counselors have the skills to tailor each session 
to address an individual’s or family’s specific needs.  Therefore, genetic counselors can play a 
significant role in providing individualized support and resources to families interested in 
research opportunities in effort to mitigate barriers faced by families. 
6.4 STUDY LIMITATIONS 
Since this study involved in-depth focus group sessions it is possible that the study attracted 
parents who are more active in the DMD community, had a strong support system, and more 
willing to discuss their thoughts, feelings, and experiences regarding research participation.  This 
may also reflect the challenges of the study to recruit families who had never participated in 
DMD research.  Though families who had not been involved in research studies in DMD were 
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represented in the study, engaging these participants was a struggle for both the research team 
and the associated CINRG/MDA clinic teams assisting with recruitment of participants.  As 
recruitment strategies were mainly carried out in a clinic setting and through shared 
communication via email and social media, participants not being followed in clinic and not 
connected within the DMD community may not have been reached and represented in the focus 
group sessions.  Although recurrent themes were identified from conversations with parent 
participants, their experiences may not be universally representative of all families in the DMD 
community. 
Additionally, available focus group dates were limited given the time commitments and 
restricted travel dates for the researchers.  Focus groups dates were based upon the schedules of 
the researchers and associated CINRG/MDA clinic team members.  To maximize convenience, 
participants were provided with at least two potential dates for focus group sessions and asked to 
respond with their preferred date.  Attempts were made to select the most convenient date and 
time for the majority of participants at a particular study site.  However, researchers were unable 
to accommodate requests by all participants and therefore, prohibited some parents from 
participating in the focus group sessions. 
Though focus groups were selected as an appropriate research method for the study, it is 
recognized that this methodology has associated limitations.82 Efforts were made to ensure 
confidentiality of research participants; however, given the nature of focus group discussions, 
absolute confidentially cannot be guaranteed.  The relatively small number of focus group 
participants limited the extent of experiences shared.  As the exchange of information in focus 
group discussions may have elicited important perspectives, it may have also hindered responses 
from participants with dissenting opinions and therefore, reflect greater consensus on a particular 
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phenomena than is warranted.  Sensitive and personal topics were brought up during focus group 
sessions in which participants may have been reluctant to provide full disclosure of their 
experiences.  The focus group moderator incorporated techniques to ensure each participant’s 
opinions were shared; however, some participants may have been reluctant to share their 
perspectives and opinions.  Additionally, as one of the project researchers and author of the 
present study, my personal experiences and relationship to DMD brought personal bias to the 
study and may have shaped the interpretation and understanding of the data. 
The present study focused solely on barriers to research participation in DMD.  This 
information may present negative connotations associated with research participation and does 
not provide a complete representation of all perspectives described by participants, including the 
many benefits and motivations to participating in research in DMD.  
6.5 FUTURE RESEARCH 
The present study is part of a larger research study aimed to understand barriers to engaging the 
DMD community in research and to develop strategies to assist with recruitment efforts.  This 
project is important to provide insight to research strategies that may increase enrollment and 
participation in research studies and may support both families participating in research and 
clinicians involved in clinical research in DMD.  As results of the present study identified many 
barriers and impacts families face when participating in DMD-related research, the larger study 
will additionally identify motivations and benefits to research participation.  Assessing benefits 
to research participation and understanding why families elect to participate in research in DMD 
will not only complement the barriers faced by families, but also inform researchers and 
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healthcare providers on benefit-risk determinations and assist with development of strategies in 
which providers can better support families interested in research opportunities.  The larger study 
also explicitly asked parents to develop a recruitment plan for research studies in DMD.  This 
data will be beneficial in the development of recruitment strategies and resources to potentially 
alleviate barriers faced by families when asked to participate in research in DMD.  Future 
research aimed at development of these strategies and incorporating participants’ suggestions 
into the clinical research process may inform ways to maintain research benefits and minimize 
the associated barriers.  Studies should be developed to assess implementation of these strategies 
into both a clinical and research setting. Additionally, as the present study only highlights the 
barriers and impacts associated with research participation as it relates to families, the larger 
study looked at the barriers to research recruitment as perceived by clinicians and researchers 
involved with research in DMD.  This data will be significant to assess areas in which parents 
and clinicians/researchers identify significant gaps in research participation in DMD and areas in 
which they share similar viewpoints on ideas for research engagement.  Future research may also 
benefit from exploring and understanding perspectives of boys and young men regarding 
participation in research in DMD. 
Results of the present study identified major commitments and additional challenges 
placed on families, complexities and educational barriers associated with research processes, and 
perceived uncertainties and risks associated with research participation in DMD.  Results from 
this study may assist with developing questionnaires and surveys to assess families’ 
understanding of research and potentially direct researchers’ and clinicians’ conversation about 
research opportunities to meet the unique needs of the families.  This information may provide a 
stronger foundation to further develop appropriate resources for patients and their families.  As 
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genetic counselors play a significant role in educating families on available research 
opportunities, future studies may explore counseling techniques and approaches utilized by 
genetic counselors to introduce families to research opportunities and to help families understand 
and adapt to the psychological and familial implications associated with participating in research 
in DMD or other rare diseases. 
Since many participants mentioned participating in research would add to the current 
challenges associated with the diagnosis of DMD, future research should aim to identify the 
appropriate time to introduce research studies to families.  Studies could assess parents’ views of 
when the most appropriate time to introduce research is compared to when providers’ deem 
introducing research studies is most appropriate.  Results of the present study highlighted a novel 
barrier to research participation expressed by some families in the DMD community as the 
inclination to ‘hold out’ for a more desirable research study.  This tendency is likely be the 
present in the larger DMD community given the increasing publicity of potentially promising 
research, such as exon-skipping trials.  Future research should explore this novel familial 
perception of research participation.  
According to the National Institutes of Health (NIH), rare diseases affect 25 to 30 million 
individuals in the United States.  Most rare diseases lack effective treatment options and present 
many challenges to the medical community.  Recruitment of eligible participants is a challenge 
for most rare disease researchers, which hinders the progress for development of effective 
treatments and increases the barriers already faced by researchers and families.28; 33 As results of 
the present study compared to similar challenges of research participation identified and 
published in other diseases, these results may be applicable to barriers and limitations to research 
participation experienced by families in other rare disease populations.8; 33; 37; 41; 42 Future 
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research should explore perceived barriers to research participation and their impact on families 
in other disease populations, as similar approaches and strategies to engaging research 
participants may be more broadly applied. 
6.6 CONCLUSIONS 
This study serves as one of the few studies to explicitly identify parent-perceived barriers to 
research participation and the impacts these barriers have on families when engaging in research 
in DMD.  The results demonstrated that electing to participate in research studies in DMD is a 
major commitment requiring planning, effort, understanding, and support from all stakeholders 
including family members, community members, and clinic/research team members.  
Participating in research was shown to affect many aspects of patients’ lives and additionally had 
an impact on the entire family.  Families should consider the commitments required and the 
potential psychosocial effects prior to engaging in research in DMD.  Due to the overwhelming 
challenges shadowing many families in the DMD community, access to appropriate resources 
and support is essential to alleviate potential barriers faced by families.  Clinic study staff, 
including genetic counselors, can assist families in exploring potential barriers and impacts on 
families.  Identifying barriers of research participation and understanding how these barriers may 
impact families have significant public health implications which can provide information to 
improve research protocols, facilitate development of educational resources, and influence public 
health policies to provide additional support to families and encourage greater research 
involvement.  Future research should assist in development of recruitment strategies and 
resources to potentially alleviate barriers faced by families when asked to participate in research 
 79 
in DMD, as similar approaches and strategies to engaging research participants may be more 
broadly applied to other rare disease populations. 
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